



# LUND UNIVERSITY

Environmental input to the pancreatic  $\beta$ -cells - the role of mechanosensitive and other ion channels

Yingying, Ye

2020

*Document Version:*  
Other version

[Link to publication](#)

*Citation for published version (APA):*

Yingying, Y. (2020). *Environmental input to the pancreatic  $\beta$ -cells - the role of mechanosensitive and other ion channels*. [Doctoral Thesis (compilation), Department of Clinical Sciences, Malmö]. Lund University, Faculty of Medicine.

*Total number of authors:*

1

## General rights

Unless other specific re-use rights are stated the following general rights apply:

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal


Read more about Creative commons licenses: <https://creativecommons.org/licenses/>

## Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

LUND UNIVERSITY

PO Box 117  
221 00 Lund  
+46 46-222 00 00



# Environmental input to the pancreatic $\beta$ -cells

- the role of mechanosensitive and other ion channels

YINGYING YE

DEPARTMENT OF CLINICAL SCIENCES, MALMÖ | LUND UNIVERSITY





# Environmental input to the pancreatic $\beta$ -cells - the role of mechanosensitive and other ion channels

Yingying Ye



**LUND**  
UNIVERSITY

DOCTORAL DISSERTATION


by due permission of the Faculty of Medicine, Lund University, Sweden.  
To be defended at “Agardhsalen CRC”, Jan Waldenströms gata 35, 205 02 Malmö  
Thursday, April 30<sup>th</sup>, 2020 at 9:00.

*Faculty opponent*  
Professor Patrick E MacDonald  
University of Alberta

<b>Organization</b> LUND UNIVERSITY	<b>Document name: DOCTORAL DISSERTATION</b>	
	<b>Date of issue: 2020-04-30</b>	
Author(s): Yingying Ye	Sponsoring organization	
<b>Title and subtitle:</b> Environmental input to the pancreatic $\beta$ -cells-the role of mechanosensitive and other ion channels		
<b>Abstract</b>		
<p>Compound input from genetic predisposition, environmental factors and lifestyle lead to <math>\beta</math>-cell dysfunction which initiates the development of type 2 diabetes. Understanding the linkage between the environmental input and gene regulatory pathways controlling <math>\beta</math>-cell function is key for developing novel therapies against T2D.</p> <p>The pancreatic <math>\beta</math>-cell is controlled by ion channels. Voltage-gated <math>Ca^{2+}</math> channels (VGCC) regulate <math>Ca^{2+}</math> signaling and insulin secretion. They are assembled with pore-forming <math>\alpha 1</math> subunits and auxiliary subunits (<math>\alpha 2\delta</math>, <math>\beta</math>, <math>\gamma</math>). Very recently, the mechanosensitive channel Piezo1 was suggested as a stimulator of insulin secretion. Mechanotransduction transduces mechanical forces into intracellular signalings and affects various cellular processes, possibly also insulin secretion. Genetic predisposition controls the susceptibility for T2D. The transcription factor TCF7L2 harbors the strongest diabetes risk gene variant and controls gene networks in insulin processing and secretion. MafA is a <math>\beta</math>-cell maturation marker, its expression is tightly associated with the differentiation state of <math>\beta</math>-cells. However, the exact mechanism behind Piezo1 regulated insulin secretion and how Tcf7l2 and MafA affect ion channels remain unknown.</p> <p><b>Results:</b> PIEZO1 is significantly upregulated in islets from T2D donors and also under the conditions of developing diabetes. Hyperglycemia triggers translocation of Piezo1 into the nucleus and normoglycemia can reverse this abnormal distribution. Inhibition of Piezo1 by GsMTx4 reduces swelling/glucose-induced <math>Ca^{2+}</math> signaling, membrane depolarization and insulin secretion. Silencing of <i>Piezo1</i> reduces <math>Ca^{2+}</math> handling and impairs glucose-stimulated insulin secretion (GSIS) while <i>yoda1</i>, the specific activator of Piezo1 induces such responses. Piezo1 regulates abundant genes (most notably <i>Cartpt</i>). Next, we generated a <math>\beta</math>-cell specific <i>Piezo1</i> knockout mouse model and ablation of <i>Piezo1</i> in <math>\beta</math>-cells results in an age-dependent effect on glucose utilization and insulin secretion. <i>Piezo1</i> deletion strongly reduced glucose-stimulated electrical activity in <math>\beta</math>-cells. These results highlight Piezo1 as a key regulator of <math>\beta</math>-cell function <i>in vivo</i> and <i>in vitro</i>.</p> <p>Tcf7l2 regulates both mRNA and protein levels of <math>\alpha 2\delta</math>-1. Suppression of <math>\alpha 2\delta</math>-1 reduces <math>Ca^{2+}</math> currents and glucose/depolarization-induced <math>Ca^{2+}</math> concentration which mimics the effect of silencing of <i>Tcf7l2</i>. Silencing of <i>Cacna2d1</i> impairs GSIS and overexpression of <math>\alpha 2\delta</math>-1 improves it by <math>\alpha 2\delta</math>-1 regulated Cav1.2 trafficking. Importantly, re-introducing <math>\alpha 2\delta</math>-1 recovers the Tcf7l2-dependent impairment of <math>Ca^{2+}</math> signaling, but not the reduced insulin secretion. Taken together, these data demonstrate that <math>\alpha 2\delta</math>-1 is the target of Tcf7l2 in controlling <math>Ca^{2+}</math>-signaling.</p> <p>Cav<math>\gamma</math>4 is downregulated in islets from hyperglycemic human donors and T2D rodent models. Silencing of <i>Cacng4</i> inhibits <math>Ca^{2+}</math> influx and insulin secretion by suppressing the expression of L-type <math>Ca^{2+}</math> channels (Cav1.2 and 1.3). MafA regulates <math>\gamma</math>4 expression by directly binding to its promoter. Cav<math>\gamma</math>4 expression is also associated with <math>\beta</math>-cell differentiation state verified by testing the de-differentiation marker Aldh1a3. These findings demonstrate that <math>\gamma</math>4 is part of MafA mediated <math>\beta</math>-cell differentiation and suggest the potential role of <math>\gamma</math>4 for correcting <math>\beta</math>-cell dysfunction.</p> <p><b>Conclusions:</b> This thesis presents evidence for novel regulatory pathways involving mechanosensor Piezo1, Tcf7l2 and MafA controlled Cav<math>\alpha 2\delta</math>-1 and <math>\gamma</math>4, respectively, for preserving <math>\beta</math>-cell function and normal insulin secretion. These findings update the current consensus model of <math>Ca^{2+}</math>-dependent insulin release. Mediating Piezo1 activity to optimize <math>\beta</math>-cell response to environmental input, recovering <math>\alpha 2\delta</math>-1 or <math>\gamma</math>4 expression to restore <math>\beta</math>-cell function may also serve as new potential therapies to T2D.</p>		
<b>Key words:</b> T2D, pancreatic islets, mechanosensitive channels, Piezo1, $\beta$ -cell specific Piezo1 knockout mouse, Tcf7l2, $\alpha 2\delta$ -1, MafA, $\gamma$ 4, $\beta$ -cell function, insulin secretion, dedifferentiation, $Ca^{2+}$ signaling, transcription factor		
Classification system and/or index terms (if any)		
Supplementary bibliographical information	<b>Language: English</b>	
<b>ISSN</b> and key title <b>1652-8220</b>	<b>ISBN 978-91-7619-909-1</b>	
Recipient's notes	<b>Number of pages 73</b>	Price
	Security classification	

I, the undersigned, being the copyright owner of the abstract of the above-mentioned dissertation, hereby grant to all reference sources permission to publish and disseminate the abstract of the above-mentioned dissertation.

Signature



Date 2020-03-25

# Environmental input to the pancreatic $\beta$ -cells - the role of mechanosensitive and other ion channels

Yingying Ye



**LUND**  
UNIVERSITY

Coverphoto: The cover picture was painted by Yingying Ye

Copyright pp 1-73 Yingying Ye

Paper 1 © by the Authors (Manuscript unpublished)

Paper 2 © by the Authors (Manuscript unpublished)

Paper 3 © Molecular and Cellular Endocrinology

Paper 4 © Communications Biology

Faculty of Medicine  
Department of Clinical Sciences, Malmö

ISBN 978-91-7619-909-1

ISSN 1652-8220

Printed in Sweden by Media-Tryck, Lund University  
Lund 2020



Media-Tryck is an environmentally certified and ISO 14001:2015 certified provider of printed material. Read more about our environmental work at [www.mediatryck.lu.se](http://www.mediatryck.lu.se)

**MADE IN SWEDEN** 

*To my family*



# Contents

Papers included in the thesis .....	8
Paper not included in the thesis.....	8
Abbreviations .....	9
<b>Introduction .....</b>	<b>11</b>
Diabetes Mellitus .....	11
Causes of Type 2 Diabetes .....	11
Insulin synthesis.....	12
Insulin action.....	13
Insulin Secretory Pathways.....	13
Triggering Pathway .....	14
Amplifying pathway.....	15
Mechano-sensing pathways.....	16
Ion channels .....	17
Mechanosensitive Ion Channel: Piezo1.....	18
Voltage-Dependent Calcium Channels .....	19
SNARE Proteins.....	23
Transcriptional factors .....	24
MafA and B .....	24
PDX1 .....	25
Ngn3 .....	25
TCF7L2 .....	26
<b>Aims .....</b>	<b>27</b>

<b>Material and Methods</b> .....	<b>29</b>
Generation of $\beta$ -cell specific Piezo1 knockout mice.....	29
Pancreas perfusion <i>in situ</i> .....	30
Patch clamp and capacitance measurement.....	31
<b>Results and Discussion</b> .....	<b>35</b>
Paper I and II .....	35
Paper III.....	42
Paper IV .....	45
<b>Future perspectives</b> .....	<b>49</b>
<b>Acknowledgment</b> .....	<b>53</b>
<b>References</b> .....	<b>57</b>

## Papers included in the thesis

- I. **Ye Y**, Barghouth M, Wang Y, Luan C, Karagiannopoulos A, Jiang X, Krus U, Eliasson L, Rorsman P, Zhang E, Renström E, The mechanosensor Piezo1 mediates glucose sensing and insulin secretion in pancreatic  $\beta$ -cells. *Manuscript*.
- II. **Ye Y**, Barghouth M, Wang Y, Fex M, Dou H, Eliasson L, Zhang E, Renström E. Beta-cell specific Piezo1 deficient mice reveal Piezo1 regulates glucose utilization and insulin secretion in rodent pancreas. *Manuscript*.
- III. **Ye Y**, Barghouth M, Luan C, Kazima A, Zhou Y, Eliasson L, Zhang E, Hansson O, Thevenin T, Renström E (2020), The TCF7L2-dependent high-voltage activated calcium channel subunit  $\alpha 2\delta 1$  controls calcium signaling in rodent pancreatic beta-cells. *Mol Cell Endocrinol*. 502: p. 110673.
- IV. Luan C, **Ye Y**, Singh T, Barghouth M, Eliasson L, Artner I, Zhang E, Renström E (2019). The calcium channel subunit gamma-4 is regulated by MafA and necessary for pancreatic beta-cell specification. *Commun Biol*. 2: p. 106.

## Paper not included in the thesis

- I. Zhang E, Mohammed Al-Amily I, Mohammed S, Luan C, Asplund O, Ahmed M, **Ye Y**, Ben-Hail D, Soni A, Vishnu N, Bompada P, De Marinis Y, Groop L, Shoshan-Barmatz V, Renström E, Wollheim CB, Salehi A (2019). Preserving Insulin Secretion in Diabetes by Inhibiting VDAC1 Overexpression and Surface Translocation in  $\beta$  Cells. *Cell Metab*. 8;29(1):64-77.e6.

## Abbreviations

T1D	Type 1 diabetes
T2D	Type 2 diabetes
GDM	Gestational diabetes mellitus
$[Ca^{2+}]_i$	Free cytosolic $Ca^{2+}$ concentration
GWAS	Genome-wide association analysis
TCF7L2	Transcription factor 7-like 2
<i>ADRA2A</i>	$\alpha$ 2A-adrenergic receptor gene
eNOS	endothelial nitric oxide synthase
Glut 2	Glucose transporter 2
GCK	enzyme glucokinase
$K_{ATP}$ channel	ATP-sensitive potassium channel
Sur	Sulfonylurea receptor
NADPH	Nicotinamide adenine dinucleotide phosphate
GSIS	Glucose-stimulated insulin secretion
SENP1	deSUMOylating enzyme
TCA	Tricarboxylic acid cycle
DIDS	4,4'-diisothiocyanatostilbene-2,2'-disulphonic acid
VRAC	Volume-regulated anion channel
Swell1	Leucine-rich repeat (LRR) containing protein
VGCC	Voltage-gated calcium channel
TRP channels	Transient Receptor Potential channels
TGH	Glycosylated hemoglobin
MS channels	Mechanosensitive ion channels
DHSt	Dehydrated hereditary stomatocytosis
VDCC	Voltage-dependent $Ca^{2+}$ channels
DHPs	Dihydropyridines
PM	Plasma membrane
TARPs	Transmembrane AMPA receptor regulatory proteins
GK rats	Goto-Kakizaki rats
SNARE	Soluble N-ethylmaleimide-sensitive factor attachment protein receptor
Vamp2	Vesicle-Associated Membrane Protein
TF	Transcriptional factors
Maf	Musculoaponeurotic fibrosarcoma oncogene family
PDX1	Pancreatic duodenal homeobox 1
IPF1	Insulin promoter factor 1
Ngn3	Neurogenin 3
TCF7L2	Transcription factor 7-like 2
GLP-1 and 2	Glucagon-like peptides
LSL	Lox-stop-lox
KO	Knockout

RIP-Cre <sup>+</sup>	Rat insulin 2 gene promoter-driven Cre
Cre <sup>+</sup> .P1 <sup>f/f</sup>	β-cell specific Piezo1 knockout mice
IPGTT	Intraperitoneal glucose tolerance test
RIA	Radioimmunoassay
RRP	Readily releasable granules
RNA-seq	RNA-sequencing
DZX	Diazoxide
GO	Gene Ontology
CART	Cocaine- and amphetamine-regulated transcript
HSIS	Hypotonicity-stimulated insulin secretion
GBP	Gabapentin
DRG	Dorsal root ganglion
Hap1	Huntingtin-associated protein 1
PKC	Protein kinase C
ER	Endoplasmic reticulum
MafA <sup>βcell</sup>	β-cell specific MafA ablation in mice
Aldh1a3	Aldehyde dehydrogenase 1A3
SPIONs	Superparamagnetic nanoparticles

# Introduction

## Diabetes Mellitus

Diabetes mellitus (hereafter referred to as ‘diabetes’) is a major health threat and one of the fastest increasing burdens to human health today. Nearly a half-billion (463 million) of people are estimated to live with diabetes today, and the number is expected to reach 700 million by 2045 [1].

Diabetes is defined as a chronically elevated blood glucose concentration, mainly caused by inadequate release of the glucose-lowering hormone insulin or inability of response to insulin in target cells (primarily in skeletal muscle, adipose tissue and liver) [1]. So far, Diabetes is presently divided into a few subtypes, the most common are type 1 diabetes (T1D), type 2 diabetes (T2D) and gestational diabetes mellitus (GDM). T2D accounts for ~90% of all diabetes globally. The phenotype of T2D is less dramatic than that of T1D, it may even be completely without symptoms initially. As a result, as many as ~50% of the T2D population might remain undiagnosed until complications such as retinopathy, cardiovascular diseases, nephropathy, or neuropathy emerge [2, 3]. These resultant severe complications have a major impact on the quality of life and life expectancy. To prevent these, early diagnosis and care for all diabetic patients are crucial. Furthermore, T2D at an early stage can be reversed (e.g. by weight loss) while T2D with longer duration has permanent pancreatic cell changes (e.g.  $\beta$ -cells) and is difficult to return to normal [4]. By preventing or taking actions to reverse pancreatic  $\beta$ -cell changes, life-threatening symptoms can be delayed, or even prevented, by proper management of diabetes. What is the ideal treatment of diabetes? To achieve this, we need to further study and understand the functions of pancreatic  $\beta$ -cells in the pathogenesis of T2D.

## Causes of Type 2 Diabetes

Pancreatic islets are clusters of endocrine cells scattered within the pancreas [5]. The islet contains five major endocrine cell types:  $\beta$ -cells (secreting insulin),  $\alpha$ -cells (glucagon),  $\delta$ -cells (somatostatin), pancreatic polypeptide (PP)-producing cells, and  $\epsilon$ -cells (ghrelin). The pancreatic  $\beta$ -cells compose the majority of the islets. Loss of

function in pancreatic  $\beta$  cells in combination with insulin resistance result in persistent hyperglycemia and T2D [6, 7]. T2D patients, even in early disease stages, lose >80% of  $\beta$ -cell function measured by disposition index (insulin secretion/insulin resistance) [8]. This indicates that loss of  $\beta$ -cell function is an early event in the development of T2D [9]. Although insulin resistance attributes to T2D, overt diabetes only occurs in the presence of progressive  $\beta$ -cell dysfunction [10].

Pancreatic  $\beta$ -cell dysfunction results from a polygenic predisposition as well as environmental factors [1, 11]. Genome-wide association analysis (GWAS) has identified a plethora of genetic variants significantly associated with  $\beta$ -cell failure and T2D [12, 13]. For example, the strongest T2D risk gene candidate *TCF7L2* is related to impaired insulin production and release [14], the underlying mechanism will be detailed later. Elevated expression of human  $\alpha$ 2A-adrenergic receptor gene *ADRA2A* is tightly related to reduced insulin secretion [15]. The gene *KCNJ11* encoding ATP-sensitive  $K^+$  channel Kir6.2 regulates the  $K^+$  inward currents to depolarize  $\beta$ -cell membrane thus stimulates insulin granule exocytosis [16].

Moreover, long-term intake of high-calorie foods, lack of physical exercise lead to weight gain and result in insulin resistance. This leads to extra requirement of insulin, but if beyond the body's compensatory capacity, it also evokes glucotoxicity and lipotoxicity that accelerate  $\beta$ -cell failure [17]. So far, the pathogenesis of  $\beta$ -cell dysfunction has attracted enormous attention, but the causes of T2D are still not fully understood. Here, I will specifically introduce some aspects influencing  $\beta$ -cell functions that are highly related to T2D development.

## Insulin synthesis

Insulin is necessary for life and the only hormone capable of lowering blood glucose. It was discovered by Frederick G Banting, Charles H Best and John James Rickard Macleod, purified by James B. Collip in 1921 [18]. Insulin is a strongly conserved protein with 51 amino acids, encoded by the *INS* gene [19-21]. Preproinsulin is translated from its mRNA, cleavage of the N-terminal peptide yields a single chain of proinsulin, which contains an A-chain (21 amino acids long) and a B chain (30 amino acids long) connected via C-peptide. Mature insulin is formed after cleavage of C-peptide, the A and B chains are retained but connected by two disulfide bonds [21]. Both mature insulin and C-peptide are co-secreted in equimolar amounts from the  $\beta$ -cell secretory granules [20, 21]. Insulin has a half life of ~6 min while ~30 min for C-peptide, which makes the measurement of C-peptide more reliable as an assessment of insulin secretion [22]. C-peptide is found to stimulate  $Na^+/K^+$ -ATPase activity and endothelial nitric oxide synthase (eNOS) [23]. C-peptide improves erythrocyte deformability in T1D patients [24]. Appropriate administration of C-peptide in T1D patients results in improved

circulatory responses by increasing blood flow in skeletal muscle [25, 26], skin microvascular [27, 28] and kidney [29].


## Insulin action

Insulin is essential for converting glucose into energy, promoting the storage and utilization of energy in the fasting and fed state, respectively [21]. The blood glucose level is controlled within a narrow range by exact regulation of insulin secretion by nervous and hormonal input, but primarily locally in the  $\beta$ -cell. Insulin is important for the metabolism of carbohydrates (blood glucose), fat (lipid storage), and also protein (branched-chain amino acids) [21]. Once insulin is secreted from the pancreatic  $\beta$ -cells upon stimulation of elevated serum glucose and enters the systemic circulation, a variety of actions are initiated by binding to the insulin receptors in target tissues [30]. The first target organ is the liver [31]. Insulin lowers blood glucose concentration by inhibiting hepatic glucose production (e.g. inhibit glycogenolysis and conversion of amino acids to glucose [21]) [32]. More than 50% of the insulin delivered to the liver is utilized and degraded [33], what remains after the first-pass clearance exits the liver and arrives at the heart via the vena cava venous circulation, is then distributed to the rest of the body following the arterial circulation. Insulin is also transported through the blood-brain barrier into the hypothalamus, hippocampus, and cerebral cortex where insulin receptors are broadly expressed and affect feeding behavior, body weight handling, etc [34]. Muscle and fat cells exposed to insulin accelerate glucose uptake by stimulating glucose transport, finally, insulin actions occur in the kidney [31].

## Insulin Secretory Pathways

In pancreatic  $\beta$ -cells from healthy individuals, increased glucose stimulates insulin secretion via a triggering pathway ( $K_{ATP}$  channels closure, depolarization-triggered activation of voltage-gated  $Ca^{2+}$  channels, and rise in free cytosolic  $[Ca^{2+}]_i$ ) and an amplifying pathway (enhancement of  $Ca^{2+}$  efficacy on insulin release). Furthermore, increasing pieces of evidence have shown the involvement of mechanosensitive ion channels (TRP channel superfamily, volume regulated anion channels, etc) in the regulation of insulin exocytosis, we name this the mechanosensing pathway. These pathways will be introduced in detail below.





**Figure 1** Brief summary of insulin secretion pathways including triggering pathway, amplifying pathway and possible mechano-sensing pathways.

## Triggering Pathway

Elevated blood glucose (e.g. postprandial) is taken up by  $\beta$ -cells through glucose transporters, Glut 2 mainly in rodents, but Glut 1, 3 and 4 predominantly facilitate glucose entry in human  $\beta$ -cells [35-37]. Metabolism of entered glucose is initiated by the enzyme glucokinase (GCK) that catalyzes glucose into glucose 6 phosphate to generate ATP via glycolysis in the mitochondria, and this also causes a concomitant fall in MgADP [10, 38]. The increased ATP/ADP ratio closes ATP-sensitive potassium ( $K_{ATP}$ ) channels, accumulation of  $K^+$  results in less negative charge inside the cell, or depolarization, of the cell membrane [39]. This triggers voltage-gated calcium channels opening for calcium ion influx, the induced cytosolic  $Ca^{2+}$  ultimately stimulates the exocytosis of insulin granules docked at the plasma membrane [40]. Conversely, at the resting state, i.e. low plasma glucose,

the  $K_{ATP}$  channels are open and the membrane stays hyperpolarized due to continuous  $K^+$  efflux, this inhibits electrical activities, prevents opening of calcium ion channels and insulin secretion [10].

Insulin secretion occurs in two phases: the first phase immediately responds to the increased glucose levels (reach the peak with 3-5 min) and lasts for ~10 min. This results from the exocytosis of predocked insulin granules in response to the elevation of  $Ca^{2+}$ , then it is followed by a long-term second phase of insulin secretion lasting for up to several hours, and that has been suggested to result from the time-consuming refilling of the releasable pool of insulin granules [41]. This physiological regulation of insulin secretion pathway has been regarded as a consensus model for decades, however, other pathways might also be involved [31, 42, 43], so is this the end of story?

### **Amplifying pathway**

Glucose is the primary stimulator of insulin secretion, but its effect is not limited to increasing ATP concentrations, controlling  $Ca^{2+}$  signaling and inducing insulin secretion. The metabolic amplification of insulin exocytosis upon glucose metabolism is also a facet of its actions. Solid evidence has developed since 1992 and a brief summary of key findings is as follows: the  $K_{ATP}$  channel opener diazoxide [44] binds to sulfonylurea receptor Sur1 (a subunit to form  $K_{ATP}$  channel) [45], prevents a majority of the effects of glucose on  $\beta$ -cell membrane depolarization, augmentation of free cytosolic  $Ca^{2+}$  ( $[Ca^{2+}]_i$ ) and insulin secretion. The application of glucose has a further augment of  $K^+$ -stimulated insulin secretion in the presence of diazoxide in rodent islets [46, 47]. Many other groups also extended this concept to human islets [48], and various insulin-secreting cell lines [49]. In contrast, when  $K_{ATP}$  channels are completely blocked by sulfonylureas, glucose still has the ability to increase insulin secretion even though the  $\beta$ -cell membrane is already depolarized and  $[Ca^{2+}]_i$  is raised [50, 51]. Mice without functional  $K_{ATP}$  channels (Sur1 knockout mice or Kir6.2 deficient mice), exhibit a relatively high “basal”  $[Ca^{2+}]_i$  and insulin secretion rate, but a transient increase in  $[Ca^{2+}]_i$  following high glucose treatment and sustained activation of insulin secretion was unsuspectedly found. This confirms the involvement of an additional amplifying pathway [52, 53]. Importantly, insulin stimulation by this pathway can be completely inhibited by  $[Ca^{2+}]_i$  influx omission [54, 55], which means that the amplifying pathway requires an initial increase in  $[Ca^{2+}]_i$  for triggering insulin release. It finally turned out that glucose has an additional effect in the amplifying pathway which is independent of  $K_{ATP}$  channels' actions and that augments the magnitude of insulin secretion. This metabolic amplification is fast and affects both the first and second phases of insulin secretion [56]. However, the exact mechanisms behind the amplifying pathway are still elusive.

Previous reports point to the importance of NADPH in the influence of insulin secretion which can be one of the regulating factors in the amplifying pathway [57]. The disturbance of the pentose phosphate pathway producing NADPH has negative effects on glucose-stimulated insulin secretion (GSIS) [58-60]. Novel techniques have been developed to measure NADPH production and its functions in the amplifying pathway [61-63], which have been improved to uncover previously little understood regulators of the amplifying pathway. Multiple studies support that the deSUMOylating enzyme SENP1 is also a contributor to the amplifying pathway [64, 65]. Pyruvate is generated by glycolysis and is transported into the mitochondria, and its metabolism is confirmed to be involved in the metabolic amplification [66], where half of the pyruvate is utilized to regenerate oxaloacetic acid (OAA) entering the tricarboxylic acid cycle (TCA) for ATP synthesis, while another half is metabolized into acetyl-CoA for yielding citrate which is the source of producing NADPH [67]. So far, researchers have only made partial breakthroughs in understanding the glucose metabolic amplification, more efforts are still needed.

In addition, weak electrical activity [46] and a slight increase in  $[Ca^{2+}]_i$  [54] were found when the  $\beta$  cells were treated with high glucose after the depolarization by high  $K^+$  in the absence of diazoxide. It indicates that the amplifying pathway can not entirely explain this situation of glucose-induced insulin secretion, other factors should also be considered [43].

### **Mechano-sensing pathways**

Besides the triggering and amplifying pathways, accumulating evidence suggests that additional ionic regulation coupled to glucose metabolism could mediate  $\beta$ -cell depolarization [68]. For instance, in isolated rat pancreatic  $\beta$ -cells, the cell volume was increased by 12% and 10% in response to 20 mM and 12 mM glucose, respectively, and this effect can be sustained when exposed to hexose, while treatment of non-metabolized 3-O-methylglucose was of no significant effect on cell volume change [69]. Furthermore, the glucose-stimulated cell volume increase showed a comparable influence on electrical activity induction [69]. Exposure to hypotonic solutions also induces  $\beta$ -cell swelling, transient electrical activity, and insulin secretion, which mimics the stimulatory effects of glucose to some extent, and these stimulatory actions can be inhibited by the anion channel blocker 4,4'-diisothiocyanatostilbene-2,2'-disulphonic acid (DIDS) [70, 71]. These findings indicate that the volume-regulated anion channel (VRAC) activation, possibly  $Cl^-$  efflux, contributes to glucose-induced depolarization in  $\beta$ -cells and insulin release [70-74]. A recent study unmasks a cell-swelling induced pathway involving the leucine-rich repeat (LRR) containing protein (Swell1) as a glucose sensor that mediates a swelling-induced chloride current and the  $\beta$ -cell membrane

depolarization that activates voltage-gated calcium channel (VGCC)-dependent calcium signalling and insulin exocytosis [75].

However, hypotonicity-induced insulin release persists even with the chloride channel blockers, DIDS or niflumic acid [76, 77]. Exposure to the hypotonic solutions leads to membrane depolarization and produces outwardly rectifying cation currents. Both these responses and hypotonic-stimulated insulin secretion can be suppressed by the cation channel blocker ( $Gd^{3+}$ ) in isolated rat islets [78]. Thus, the proposition is that stretch-activated cation channels might be involved in the swelling-induced insulin secretion [78].

TRP (Transient Receptor Potential) channels belong to the mechanosensitive superfamily. An increasing number of data point to abundant expression of TRP channels in pancreatic  $\beta$ -cells and their potential regulation of insulin release. Expression of *Trpc1*, *Trpv2*, *Trpv4*, *Trpm2-5* in mouse islets and *Trpc1*, *Trpc4*, *Trpv5*, and *Trpm2* in rat islets or  $\beta$ -cells have been reported [79]. TRPV5-6 are found in human pancreas, and the transcripts of TRPM2, TRPM4-5 are detected in human islets [80, 81]. They are activated by a variety of stimuli including cell swelling, voltage, ligand binding, temperature, etc [82]. *Trpm5* is involved in the regulation of  $Ca^{2+}$  oscillations and contributes to insulin secretion in pancreatic  $\beta$ -cells [83, 84]. *Trpm5* deficient pancreatic islets show reduced membrane potential, cytosolic free  $Ca^{2+}$  concentration and significant impairment in GSIS [84]. By measuring total glycosylated hemoglobin (TGH) from 997 pregnant women, mutations in TRPM6 are associated with higher TGH and leading to gestational diabetes mellitus [85]. Glucose and GLP-1 activated *Trpm2* effectively depolarizes the cell membrane and initiates insulin secretion, whereas it is attenuated in *Trpm2* deleted mice [86]. Repeated observations made found that *Trpv1* does not contribute to GSIS but might be involved in insulin sensitivity [87, 88]. *Trpv2* channel is confirmed to be activated by osmotic-cell-swelling in mouse  $\beta$ -cells, resulting in membrane depolarization and subsequently voltage-gated  $Ca^{2+}$  channels activation and insulin secretion [89]. Recently, the mechanosensitive channels, Piezo1 (*Fam38a*) and Piezo2 (*Fam38b*) were identified as the long-sought-after mechanosensitive cation channels involved in mechanotransduction processes [90]. Their functions have since started to unravel, so are they potential candidates as sensors of cell swelling resulting from glucose metabolism and regulation of insulin secretion? This is the main question we will address in this thesis.

## Ion channels

Ion channels are macromolecular complexes that span across the lipid bilayer of the cell membrane [91]. Different types of ion channels respond to either electrical activity (voltage-dependent ion channels), mechanical forces (mechanosensitive ion

channels), or chemical stimuli (ligand-gated ion channels), etc, result in small conformational changes to open the channels [92]. The deformation of the channels allows ions to enter or exit the cell. In general, the function of an ion channel is determined by the activity (conductance and open property) or the number of the channel in the cell surface [93].

As mentioned in the previous,  $\text{Ca}^{2+}$  is a mandatory signal and plays crucial roles in a variety of  $\beta$ -cell pathways involved in insulin secretion.  $\beta$ -cells possess numerous channels that influence  $\text{Ca}^{2+}$  signaling, such as voltage-gated  $\text{Ca}^{2+}$  channels and the newfound mechanosensitive ion channels. When the  $\beta$ -cells are exposed to stressful conditions during the pathogenesis of T2D, it results in perturbations in ion channel expressions, activities or localizations, which consequently alters  $\text{Ca}^{2+}$  handling. The defect in  $\text{Ca}^{2+}$  signaling of diabetic  $\beta$ -cells impairs insulin secretion and aggravates hyperglycemia [94].


### **Mechanosensitive Ion Channel: Piezo1**

Mechanotransduction, the conversion of mechanical forces from the environment into biological signals, is crucial for survival. For instance, senses of touch, respiration, hearing, bladder control, the circulatory system and blood pressure regulation, etc, are regulated by mechanosensitive ion channels (MS channels also known as stretch-gated ion channels) [95, 96]. The existence of MS channels was first identified in 1984 in chick pectoral muscle [97]. Since then, MS channels have been found to be ubiquitously expressed in organisms from the three kingdoms of life including bacteria, archaea, and eukarya. Their structure and functions have been understood greatly, especially the discovery and cloning of Piezo1 and Piezo2 channels in 2010 [90] opened up the floodgates for a dramatic number of mechanotransduction-related research. Piezos are pore-forming homo-oligomer ion channels that can be stimulated by mechanical stimuli including membrane perturbation and osmotic imbalance, independent from the assistance of other cellular components [98, 99].

Piezo1 is a very large protein (see Figure 2) with a full-length of 2547 amino acids forming a trimeric propeller-like (some reported as bowl-like shape [100]) structure with three distal blades and a central cap [101]. Residues 1-2190 sense the mechanical forces and determine the open property of the pore of the channel laid in the C-terminal (residues 2189-2547) [99], which is responsible for the entry of positively charged ions with a slight preference for  $\text{Ca}^{2+}$  into the cells, and generates an overall depolarizing effect [90, 102]. To determine whether changed membrane tension is enough to activate Piezo1, overexpression of Piezo1 in the artificial cell membrane (cytoskeleton free) has been shown to directly sense the force from the bilayer tension [103]. The deformation of Piezo1 into a planar structure in response to membrane-perturbations-generated lateral membrane tension is responsible for

channel gating, as demonstrated by cryo-electron microscopy and high-speed atomic force microscopy [100, 104].

Piezo1 is broadly expressed at high levels in skin, bladder, kidney, lung and urothelium which are exposed to pressure and fluid flow [90, 105, 106]. General knockout of Piezo1 in mouse is embryonically lethal, owing to at least in part to the disrupted development of the vasculature system [107, 108], indicating its essential role for fundamental life processes. Consistent with the phenotype, Piezo1 senses the extension of bladder [106], senses shear stress of blood flow for proper blood vessel development [107, 108], regulates red blood cell volume [109], controls cell migration and proliferation [110]. In humans, mutations of *Piezo1* resulting in altered channel functions have been linked to multiple hereditary human diseases, like dehydrated hereditary stomatocytosis (DHSt) which is linked to gain-of-function mutations in PIEZO1 ion channels [111]. *PIEZO1* (SNP rs9933309) was revealed as novel loci (within top 7 hits) harboring common variants associated with HbA1c in East Asians, affecting erythrocyte parameters rather than glucose metabolism, such variants could be relevant to the use of HbA1c for diagnosing diabetes [112]. Furthermore, the Piezo1 agonist yoda1 treatment induces insulin secretion in insulin-secreting  $\beta$ -cell lines and rodent pancreatic islets [113]. Taken together, these suggest that Piezo1 could be an important player for the regulation of insulin secretion in  $\beta$ -cells and pathogenesis of T2D, which are well studied in Paper I and II.



**Figure 2** Illustration of the mechanotransduction and pore modules of the mPiezo1 channel [99-101, 114]. Changes of membrane tension driven by osmotic imbalance or asymmetric lipid bilayers are sensed by the transmembrane modules and the Piezo1 channel is open for positive ion entry. CED: C-terminal extracellular domain; Blade: Extracellular peripheral regions.


## Voltage-Dependent Calcium Channels

Voltage-dependent  $\text{Ca}^{2+}$  channels (VDCC) take the most important role for the finely tuned balance of  $\text{Ca}^{2+}$  entry and efflux at the plasma membrane [82]. By doing

so, hormone secretion is tightly controlled to ensure proper pancreatic  $\beta$ -cell function.

Based on the structure, functional VDCCs contain the pore-forming  $\alpha 1$  subunits which are subdivided into three main groups (see classification in Figure 3): the Cav1, Cav2, and Cav3 channels. The Cav1.1, Cav1.2, Cav1.3 and Cav1.4 channels encoded by *CACNA1S*, *-C*, *-D* and *F*, also known as L-type calcium channels, are sensitive to dihydropyridines (DHPs), such as isradipine [115, 116]. The Cav2.1 (also referred to as P/Q-type), Cav2.2 (N-type), Cav2.3 (R-type) channels are encoded by *CACNA1A*, *-B* and *-E*, respectively [117-119]. Both Cav1 and Cav2 channels are gated by high-voltage, termed as high-voltage activated channels (HVA). They are slowly inactivated during a sustained depolarization, so-called long-lasting activation [82, 120]. Cav3.1-3.3 channels, encoded by *CACNA1G*, *-H* and *-I* [121-123] are activated at a relatively lower voltage ( $\sim -55$  mV) and inactivated at  $\sim -40$  mV which sustains in a brief depolarization [82].

The L-type calcium channels (mainly Cav1.2 and Cav1.3) are expressed in pancreatic  $\beta$ -cells and carry the majority of voltage-gated  $\text{Ca}^{2+}$  currents, influence GSIS [82, 120, 124, 125]. Cav1.1 and Cav1.4 are mainly found in skeletal muscle and retina cells, respectively, whereas scarcely detected in  $\beta$ -cells [125].  $\beta$ -cell specific Cav1.2 knockout mice showed a  $\sim 45\%$  decrease in the whole-cell  $\text{Ca}^{2+}$  current and abolished the first-phase insulin secretion resulting in glucose intolerance [120]. Silencing of *Cacna1d* (Cav1.3) decreases GSIS in insulin-secreting  $\beta$ -cells (INS-1 832/13 cells) and also impairs exocytosis in human islets [126]. Taken together, defects in the L-type calcium channels especially Cav1.2 and Cav1.3 are suggested to be involved in the development of diabetes.



**Figure 3** Classification of Voltage-dependent  $\text{Ca}^{2+}$  channels, modified from [127].

VDCCs also consist of multiple auxiliary subunits including  $\alpha 2\delta$ ,  $\beta$  and  $\gamma$  subunits attaching to the pore-forming  $\alpha 1$  subunit and modulate the VDCC's functions. Either the Cav1 or Cav2 subtypes of VDCCs are capable to form a heteromeric complex, assembling with one of the  $\beta$  subunits (*CACNB1-4*) and one of the  $\alpha 2\delta$  subunits (*CACNA2D1-4*); For Cav3 channels, these can be formed by  $\alpha 1$  subunit alone without auxiliary subunits [128].  $\gamma$  subunits contain 8 isoforms ( $\gamma 1-8$ ),  $\gamma 4$ ,  $\gamma 6$ ,  $\gamma 7$ , and  $\gamma 8$  subunits are demonstrated to physically associate with the Cav1.2 channel in cardiac tissue [129, 130]. The  $\gamma 1$  subunit interacts with Cav1.1 channel in rabbit skeletal muscle [131]. Neuronal  $\text{Ca}^{2+}$  channels (Cav2.1 and Cav2.2) physically bind to  $\gamma 2$ ,  $\gamma 3$  and  $\gamma 4$  [132, 133]. Therefore, the  $\alpha 1$  subunits of VDCCs except Cav3 channels also associate with  $\alpha 2\delta$ ,  $\beta$  and  $\gamma$  subunits (Figure 4).

#### *Cav $\alpha 2\delta$ subunit*

The  $\alpha 2\delta$  subunit is primarily identified in the skeletal muscle together with Cav1.1 [134-137] and its molecular cloning was accomplished in 1988 [138]. Subsequently, N-type calcium channel is found to tightly interact with  $\alpha 2\delta$  subunit in rabbit brain [139]. The  $\alpha 2\delta$  subunit is encoded by a single gene, but during post-translational modification, it is cleaved into a glycosylated  $\alpha 2$  protein which hangs extracellularly and a  $\delta$  subunit spanning the membrane, these two separate proteins are connected by a disulfide bond as a mature subunit [125].


The  $\alpha 2\delta$  and  $\beta$  subunits control the trafficking of VDCCs to the plasma membrane (PM) and also affect the channels' biophysical properties [140]. They also serve as stimulators for the expression of different Cav1 or Cav2 channels, either in functional expression or absolute amount of proteins at the plasma membrane, thus cause an increase of  $\text{Ca}^{2+}$  current amplitude and changes in current kinetics [141-145]. Cav2.2 channel expression in the plasma membrane is increased with  $\alpha 2\delta$ -1 [146], and the resultant  $\text{Ca}^{2+}$  currents carried by Cav2.2 are induced by approximately 10-fold [147], indicating the importance of  $\alpha 2\delta$ -1 on  $\text{Ca}^{2+}$  current density. Moreover, male mice with genetic ablation of  $\alpha 2\delta$ -1 show a decreased  $\text{Ca}^{2+}$  influx through all types of functional VDCCs in pancreatic  $\beta$ -cells, which lead to the reduction of insulin secretion and glucose tolerance impairment [148]. However, the detailed cellular mechanisms regarding the single  $\beta$ -cell level needs to be explored (Paper III).

#### *Cav $\gamma 4$ subunit*

The eight isoforms of the  $\gamma$  subunits are clustered into three subgroups: I.  $\gamma 1$ ,  $\gamma 6$ , II.  $\gamma 5$ ,  $\gamma 7$ , and III.  $\gamma 2$ ,  $\gamma 3$ ,  $\gamma 4$ ,  $\gamma 8$  according to the sequence homology and chromosomal linkage [149, 150]. Both  $\gamma 1$  and  $\gamma 6$  structurally lack a PSD-95/DLG/ZO-1 (PDZ)-binding motif and might also share physiological functions that distinct from most other  $\gamma$  subunits [150]. The pairwise amino acid identity of  $\gamma 5$  is closest to  $\gamma 7$  [149]. Cav $\gamma 2$ ,  $\gamma 3$ ,  $\gamma 4$ , and  $\gamma 8$  are regarded as transmembrane AMPA receptor regulatory proteins (TARPs) [151].  $\gamma 4$  is broadly expressed in brain especially in fetal brain,



substantially distributes in lung and prostate, and is expressed relatively lower in pancreas, stomach, testes, etc [152]. RNA-sequencing data shows that *CACNG4* ( $\gamma4$ ) is expressed in human  $\beta$  cell lines (EndoC- $\beta$ H1 and - $\beta$ H2 cells) [153]. Furthermore, calcium channels including *Cacna1d* (Cav1.3), *Cacna2d1* (Cav $\alpha2\delta1$ ), and *Cacng4* (Cav $\gamma4$ ) are downregulated in Goto-Kakizaki (GK) type 2 diabetic rats, which provides the molecular basis of the correlation between reduced L-type  $\text{Ca}^{2+}$  currents and low heart rate in GK rats [154]. The expression of  $\gamma4$  in fetal brain shows a precise time correlation with the onset of neuronal differentiation, which indicates the potential role of  $\gamma4$  in neuronal development, and  $\gamma4$  might mediate cell differentiation by regulation of cytosol  $\text{Ca}^{2+}$  levels through VDCCs [155]. Several reports have shown differential modulations of  $\gamma4$  on  $\text{Ca}^{2+}$  channel functions, it significantly shifts the  $\text{Ca}^{2+}$  current inactivation curves to more positive voltages when coexpressed with Cav3.1 [152]. When  $\gamma2$  and  $\gamma4$  subunits are coexpressed with Cav2.1, they shift the steady-state inactivation curve to more hyperpolarized potentials [156]. These data demonstrate that the  $\gamma4$  subunit is part of the regulation of activation and inactivation of VDCCs. Collectively, these suggest to us to explore the potential roles of  $\gamma4$  in healthy and diabetic conditions, which is developed in Paper IV.



**Figure 4** Structure of voltage-dependent calcium channel including  $\alpha1$ ,  $\alpha2\delta$ ,  $\beta$  and  $\gamma$  subunits anchoring in the plasma membrane.

## SNARE Proteins

Insulin exocytosis requires membrane fusion of insulin-containing granules mediated by a family of proteins referred to as soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. The docking, tethering and fusion of the insulin granules with the plasma membrane are highly controlled to ensure proper secretion of insulin into the extracellular environment [157]. The SNARE complex consists of Syntaxin, Snap-25 in the plasma membrane and Vamp2 (Vesicle-Associated Membrane Protein) in the secretory granule membrane. The association of these proteins is orchestrated by Munc18, Munc13 and RIM (the active zone protein, which plays a leading role in vesicle docking) [158-160]. A stable  $\alpha$ -helical ternary complex is formed after finishing recruiting all of these proteins and is prepared for membrane fusion [157]. The detailed molecular machinery is comprehensively described in [39, 42, 157, 161].

Insulin-secreting cells express a full complement of SNARE proteins which are similar to those involved in synaptic vesicle exocytotic machinery in the neuron [161]. Disturbance of these proteins results in impairment of exocytosis [157, 162, 163]. The deduction of the peak secretion of first-phase GSIS has been partially attributed to the reduced predocked secretory granules which is mediated by Munc18a/SNARE complex [164, 165]. For instance, Munc18a has been demonstrated to control the first-phase insulin secretion [166] because of its key role in the priming of insulin vesicle for exocytosis [167]. Stx1a expression is found severely reduced in the islets of T2D, a  $\beta$ -cell specific *Stx1a* knockout mouse model shows decreased blood insulin level corresponding to the elevation of blood glucose, molecularly attributes to the deficiency of *Stx1a* remarkably decreases readily releasable pool and granule pool refilling, thus results in the impairment of both phases of GSIS [168]. SNAP25 expression is also decreased in the islets of T2D [165, 169] and is negatively correlated to HbA1c levels *in vivo*, positively correlated with GSIS *in vitro* [169], which suggests that SNAP25 is essential for insulin secretion in both human and mouse islets. VAMP/Vamp2 is highly expressed in both human and mouse  $\beta$ -cells [42] and it shows a negative correlation with HbA1c in human islets [169]. Vamp2 mediates the exocytosis of predocked insulin granules while Vamp8 is the major determining factor for the fusion of newcomer insulin granules [161]. Some novel ideas concerning the regulation of Munc18a/SNARE proteins are demonstrated in Paper III of this thesis.

## Transcriptional factors

Mature pancreatic  $\beta$ -cells initiate from embryonic stem cells via an orchestrated cellular process known as differentiation. Differentiation is tightly controlled and coordinated by specific gene regulators in a time-dependent manner, and develops particular morphological and functional cellular features. For instance, maturation of  $\beta$ -cells enables them to release an appropriate amount of insulin in response to fluctuating glucose concentrations [170]. However, mature  $\beta$ -cells can lose their cellular identities and differentiated phenotypes to various degrees and regress to an immature or a precursor-like status under certain conditions, this process is termed as dedifferentiation which contributes to the loss of functional  $\beta$ -cell mass in T2D [6, 171-173]. In the progress of differentiation, numerous transcriptional factors (TF) are critically involved and play integral roles to direct cell destinies by regulating the transcription of their downstream genes in the line of cell maturation [174]. Examples are listed below as well as a summary of TFs in differentiation in Figure 5.

### **MafA and B**

Among transcriptional factors (TF), MafA and B (musculoaponeurotic fibrosarcoma oncogene family A and B) appear to be islet-enriched TFs, play a fundamental role in the development of  $\beta$ -cell identity and functionality [175]. Expression of MafB is higher in rodent embryonic  $\beta$ -cells and is downregulated rapidly after birth, is substituted progressively by MafA in the progress of  $\beta$ -cells maturation, it is then restricted to  $\alpha$ -cells 3 weeks after birth [176, 177]. Ablation of *MafB* in embryos reduces the amount of insulin<sup>+</sup> and glucagon<sup>+</sup> cells during the development without changing the total amount of endocrine cells, and the expression of MafA is delayed as well as the production of insulin<sup>+</sup> cells [177]. MafA is particularly expressed in mature  $\beta$ -cells, known as a maturation marker, which directly regulates insulin production and Glut2 [175]. Knockout of *MafA* in mice severely impairs glucose-, KCl-, or arginine-stimulated insulin secretion, leads to the development of glucose intolerance and T2D [178]. MafA expression is reduced in the diabetic mouse model (*db/db* mice) and human T2D islets, which suggests a potential signature of  $\beta$ -cell dysfunction [179]. Overexpression of MafA in immature rat islets and other insulin-secreting cells stimulates GSIS, which might owe to its regulation of a number of genes related to insulin secretion [178, 180, 181]. A dramatic amount of data, not limited to the above, provide support for the importance of MafA and B in  $\beta$ -cell development, regulation of insulin and other crucial genes [182-184].


## **PDX1**

PDX1 (Pancreatic duodenal homeobox 1), also known as insulin promoter factor 1 (IPF1) manifests its role throughout all stages of pancreatic development [174]. Pdx1 can be detected in the early developing embryo from E8.5 in mouse [185] and week 4 gestation in human [186]. The developing of pancreas is arrested when Pdx1 is blocked from E11.5 in the pregnant mice, no  $\beta$ - or acinar-cells are found in the pancreas at birth [187]. Pdx1 binds to the insulin promoter, therefore, deletion of *Pdx1* in mature  $\beta$ -cells reduces insulin production and impairs glucose homeostasis [187].  $\beta$ -cell specific knockout of *Pdx1* leads to severe hyperglycemia and the *Pdx1*-deleted cells rapidly achieve  $\alpha$ -cell-like ultrastructural and physiological characteristics, and MafB starts to express in the reprogrammed cells, indicating Pdx1 as a crucial regulator of  $\beta$ -cell fate and is essential to maintain  $\beta$ -cell identity [188].

## **Ngn3**

Neurogenin 3 (Ngn3) is also one of the most important TFs for endocrine development. *Ngn3* null mice are lack of islets, develop into T1D and die within 3 days after birth [189]. Ngn3 interacts with a few downstream TFs including Nkx6.1, Nkx2.2, Isl1, Pax4, Pax6, Pdx1 and NeuroD1, required for endocrine development and maintenance of cell identity [190-192].

In summary, TFs exert vital roles in the maturation process of pancreatic cells. Understanding the details of the mechanisms is a benefit for preventing the loss of maturity or restoring the differentiated state of  $\beta$ -cells in T2D.



**Figure 5 Selection of transcription factors (TFs) landmarks during pancreatic cell development.** Low expressions of TFs are indicated in parentheses. Modified from [193].

## TCF7L2

A common genetic variant encoding the transcription factor 7-like 2 (TCF7L2, also known as TCF4) attributed to the single-nucleotide polymorphism (SNP rs7903146) has the strongest genetic risk for the development of T2D, revealed by genome-wide associate studies [194-196]. The risk T-allele of rs7903146 increases 1.5-fold of T2D risk and 2.4-fold in heterozygous and homozygous carriers, respectively, corresponding to a 21% population risk [197]. From a cellular functional view, TCF7L2 is a key effector in the Wnt signaling pathway which is involved in cellular growth and organogenesis [196, 198, 199], as well as in adipogenesis [195],  $\beta$ -cell survival and functions in human and mouse islets [200]. A TCF7L2-regulated transcriptional gene network, affecting insulin production and processing in human and rodent pancreatic islets, has been identified by RNA-sequencing. Among these genes, *ISL1*, *MAFA*, *PDX1*, *NKX6.1*, *PCSK1*, 2 and *SLC30A8* are highlighted and confirmed to be associated with *TCF7L2* [14]. TCF7L2 also influences insulin secretion by regulating the transcription of various proteins such as proglucagon and glucagon-like peptides (GLP-1 and 2) [201, 202]. Silencing of *Tcf7l2* markedly reduces the mRNA expression of *Cacna2d1* (the aforementioned Cav channel subunit) but does not influence the genes controlling  $Ca^{2+}$  signaling and exocytosis [14]. Therefore, it is worthy to verify the regulatory effects of *Tcf7l2* on *Cava2d1* as well as how this influences  $Ca^{2+}$  signaling and insulin secretion in pancreatic  $\beta$ -cells, which is detailed in Paper III.

# Aims

Development of diabetes, especially T2D, attributes not only to genetic factors, but also environmental input. As aforementioned, insulin-secreting pancreatic  $\beta$ -cells can adjust their state in response to high glucose or osmolarity imbalance versus the extracellular space. Increasing evidence has indicated the involvement of mechanosensitive channels in this respect. However, the effectors behind the regulatory pathway are not fully unraveled. The transcription factor TCF7L2 is the strongest diabetes risk gene, MafA is important for the development and identity maintenance of  $\beta$ -cells. VGCCs play key roles in insulin secretion and highly correlate with T2D. However, the regulation of TCF7L2 and MAFA on the auxiliary subunits such as  $\alpha 2\delta$ ,  $\gamma$  subunits associated with Cav $\alpha 1$  are not completely understood in islet  $\beta$ -cells. In this thesis, we aim to develop a novel insulin secretion pathway involving mechanosensor Piezo1 *in vitro/ in vivo*, also the roles of Tcf7l2 and MafA in controlling  $\beta$ -cell function via the auxiliary subunits  $\alpha 2\delta 1$ ,  $\gamma 4$  subunits, respectively.

## The Specific Aims of the Thesis:

- I. To explore the involvement of the mechanosensitive channel Piezo1 in the insulin secretion pathway in pancreatic  $\beta$ -cells.
- II. To investigate the role of Piezo1 *in vivo* in  $\beta$ -cell specific *Piezo1* knockout mice.
- III. To study the regulation by the diabetes risk gene Tcf7l2 of the voltage-gated calcium ion channel subunit Cav $\alpha 2\delta$ -1 and, in turn, Ca<sup>2+</sup> signaling and insulin secretion.
- IV. To examine the physiological mechanisms whereby MafA regulates Cav $\gamma 4$  affects pancreatic  $\beta$ -cell function.



# Material and Methods

Here only the methods that needed more detailed descriptions will be considered. Readers are referred to the original papers for other methods used in the studies included in this thesis.

## Generation of $\beta$ -cell specific *Piezo1* knockout mice


The Cre-loxP recombinase system has been commonly utilized to delete genes or activate reporters in pancreatic cells in mice. It is an indispensable tool to investigate the cell-, tissue- and/or developmental stage-specific functions of the target gene in the pathophysiology of diabetes. The P1 bacteriophage-derived Cre recombinase is a 38 kD homotetramer, recognizes the 34 bp loxP sequence and excises the loxP-flanked DNA sequence (normally contains one or more exons). The Cre-mediated recombination is guided by the orientation of loxP sites. Inversion or excision occurs when the loxP sites localize on the same strand of DNA, while it performs insertion when they are on separate strands [203]. Similarly, to activate the expression of the target gene conditionally, the Cre recombinase recognizes the allele containing a lox-stop-lox (LSL) sequence to induce the expression of the coding sequences [204]. Recombination mediated by Cre can be controlled by regulating the timing or spatial distribution of Cre expression [203], like the line Cre<sup>ER</sup> which enables temporal regulation of Cre recombination by activation of tamoxifen [205]. There are at least 79 pancreas-specific Cre driver lines which can be subdivided into four categories according to the Cre expressed cell types: endocrine, exocrine, ductal and pancreatic progenitor cells [204]. The first three categories are distinguished by cell-type-specific genes such as hormones or digestive enzymes that mark individual cells in the pancreas; The fourth category is normally used for studies of development and functions of the pancreas. The new floxed alleles development by introducing the embryonic stem cells with mutant allele into the germline of mice has been improved which allows a diverse generation of conditional knockout mice.

Global knockout of *Piezo1* mouse model is embryonically lethal [107, 108], to evaluate the specific function of *Piezo1* in pancreatic  $\beta$ -cells *in vivo*,  $\beta$ -cell-specific *Piezo1* knockout (KO) mice are therefore warranted. To this end, we use the mice expressing rat insulin 2 gene promoter-driven Cre (RIP-Cre<sup>+</sup>) [206] and the floxed



*Piezo1*<sup>tm2.1Apat/J</sup> (*P1*<sup>f</sup>) mice whose *Piezo1* has been engineered to incorporate loxP sites from exon 20 to 23 (Stock #029213, The Jackson Laboratory) [109] in this thesis. The two lines of mice were mated to obtain RIP-Cre<sup>+</sup>. *P1*<sup>f/+</sup> mice, which were then crossed with *P1*<sup>f</sup> to get RIP-Cre<sup>+</sup>.*P1*<sup>f/f</sup> KO mice (Figure 6). The tail samples from the litters were genotyped following the protocol from the Jackson Laboratory, the gene depletion state was further confirmed by testing *Piezo1* mRNA and protein levels in whole islets and single  $\beta$ -cells, respectively.

Due to the limitations of Cre/loxP system and the known deficiencies of a given mouse line, one has to prudently draw scientific conclusions from the results by using this strategy. The RIP-Cre line (Tg(*Ins2-cre*)<sup>23HerT</sup>) we used was confirmed normoglycemic and the islets from these mice are histologically normal as well [206], the blood glucose post intraperitoneal glucose tolerance test (IPGTT) of Cre and floxed *Piezo1* mouse line was also compared by us and both appear normal, but the leaky expression in the neuroendocrine cells and the brain should be also kept in mind [207, 208].




**Figure 6.** Scheme illustration of generation of  $\beta$ -cell specific *Piezo1* knockout mice. Generation of *Piezo1*<sup>tm2.1Apat/J</sup> (*P1*<sup>f</sup>) refers to [109], FRT: FLP recombinase target

## Pancreas perfusion *in situ*

To investigate the physiological functions from both endocrine and exocrine tissue in the pancreas, *in situ* pancreas perfusion is performed [209, 210]. In contrast to the studies in isolated islets, this method mimics the *in vivo* conditions meanwhile eliminates the secondary effects of other organs. Pancreas perfusion has the advantage of detecting small changes in a dynamic view of insulin secretion in response to different pharmacological drugs and/or nutrients (e.g. glucose). This

method has been utilized for investigating physiological pancreatic functions related to T2D [211-214]. It is a useful tool for the exploration of potential therapeutic candidates especially to insulin secretion regulation [215].

First, the anticoagulant heparin (2000 units/kg) is intraperitoneally injected in the non-fasted C57BL/6J mouse to prevent the blood clots from compromising the system. Then the mouse is sacrificed by a rising concentration of CO<sub>2</sub>. After opening the abdominal cavity, the renal, hepatic, splenic, superior mesenteric and inferior mesenteric arteries are ligated, the aorta is tied off above the level of the pancreatic artery (A double ligature is preferable to prevent the leakage during the perfusion due to incomplete ligation). A silicone catheter connected cannula Butterfly needle (27 G) is placed in the celiac aorta which is the site for the entry of testing solutions. The perfusate is collected at an interval of 1 min via the portal vein with a silicone catheter connected cannula Butterfly needle. The mouse is kept on a heating pad (37°C) during the perfusion. The pancreas is perfused with a mixture of Krebs-Ringer buffer containing 1mg/ml BSA and glucose/drugs as indicated (filtered with Filtropur S 0.2 unit) at a rate of 1 ml/min using a KDS Legato 100 series syringe pump. The buffer is priorly equilibrated with O<sub>2</sub>/CO<sub>2</sub> (95:5) resulting in a pH range of 7.28 to 7.40. Preperfusion with 2.8 mM glucose Krebs buffer is required to flush out the blood as well as to maintain a basal level of insulin secretion and pancreas function. The production of insulin in the collected perfusate is a reflection of the responsiveness to glucose/drugs/hypotonicity/other secretagogues and is measured by radioimmunoassay (RIA).



**Figure 7.** The perfusion setup (left) and illustration of ligations in arteries (right).

## Patch clamp and capacitance measurement

The patch-clamp technique was developed in 1976 by Neher and Sakmann, it has been widely used to record the whole-cell or single-channel currents through the ion channels embedded in the cell membrane [216, 217]. This technique is commonly

applied to study the electrophysiology of specific ion channels in excitable cells such as neurons and pancreatic  $\beta$ -cells.

By controlling the voltage (voltage clamp) or current (current clamp), the experimenter can record the resulting changes in current or voltage (membrane potential) across the cell membrane, respectively. Depending on the specific purpose of the study, several variations can be selected, including the whole-cell patch and perforated patch which allow investigators to study the summed electrical activities of the ion channels in the entire cell, and the inside-out/outside-out techniques in which a section of membrane is removed from the cell to study the behavior of single ion channel in the excised patch.

In this thesis, we used voltage clamp to investigate the  $\text{Ca}^{2+}$  currents in a whole-cell configuration. In practice, an AgCl coated silver electrode is placed into the micropipette (thin and blunt-tipped) filled with intracellular solution, the pipette is pressed onto the cell surface, the experimenter applies gentle suction to form a giga-seal with high electrical resistance ( $>1 \text{ G}\Omega$ ). As soon as the giga-seal is established, voltage is simultaneously applied, the patch of membrane is then ruptured by a pulse of negative pressure (short suction) in the whole-cell configuration. The electrode in the micropipette now is a part of the electric circuit. It records real-time results about both current (magnitude and direction of the ion flow) and the time for activation or inactivation of the individual channels. Here, the  $\text{Ca}^{2+}$  currents were monitored using a software (Pulse or Patchmaster) controlled amplifier (EPC9 or EPC10, HEKA) connected to the electrode.

In patch-clamp, a good and stable gigaseal between the pipette and cell membrane is the fundamental requirement for achieving stable configurations and avoiding current leaking. For whole-cell configuration, the cytosolic content in the cell is replaced over time by the intracellular solution in the pipette. The composition of the solution can be adjusted to fit the purpose of the study, however, it might also affect certain cellular functions by dialyzing the interior of the cell. Therefore, perforated patch is an alternative method to evade this issue. The membrane of the cell on detection is perforated by pore-forming antibiotics (e.g. amphotericin), the cell is maintained as integrated which only allows a permeability of small monovalent ions ( $<200 \text{ Dalton}$ ). Therefore, this configuration is more stable than the conventional whole-cell mode and also prevents rundown of currents [216, 218, 219], while it's more demanding for a stable setup of the recording system and also time-consuming.

Patch clamp is not only used for recording the activities of ion channels, granule exocytosis can also be measured. The cell membrane serves as an electrical capacitor due to its lipid bilayer structure. The capacitance ( $C$ ) is calculated according to equation [220] as below:

$$C = (\epsilon \times A)/d$$

Where  $A$  represents the area of the cell surface,  $\epsilon$  and  $d$  are constant which stand for the specific capacitance ( $0.9 \text{ fF}/\mu\text{m}^2$ ), and the distance between the bilayer of phospholipids, respectively. Therefore, the changes of capacitance ( $C$ ) proportionally reflect changes in cell surface area ( $A$ ).

In  $\beta$ -cells, exocytosis occurs when insulin granule fuses with the cell membrane and it leads to an expansion of the cell surface area. Hence, this increase in cell surface can be detected as an increase in capacitance representing exocytosis [221]. The fusion of a single vesicle is estimated to produce an increase in membrane capacitance of  $3.6 \text{ fF}$  [39]. To note, this method is not able to distinguish the exocytosis and concomitant endocytosis since it records the total changes in cell surface area. However, the maximum rate of endocytosis is much lower than that of exocytosis [222]. Moreover, upon stimulation, fusion of synaptic-like vesicles or organelles also occurs which might affect the results [39], even though it only contributes  $\sim 1\%$  to the total capacitance [223]. These should be kept in mind during data interpretation.

In this thesis, INS-1 832/13 cells, dispersed human or rodent islets were used for the experiments. The pipettes had an average of resistance at  $\approx 5.5 \text{ M}\Omega$  and the temperature in the bath solution was maintained at  $32^\circ\text{C}$ . Holding- and test-pulse were conducted by the software-controlled amplifier with a specific protocol to record the  $\text{Ca}^{2+}$  currents. The increase in membrane capacitance was evoked by a train of ten membrane pulses from  $-70 \text{ mV}$  to  $0 \text{ mV}$  for  $500 \text{ ms}$  applied at  $1 \text{ kHz}$  sine wave. The first two depolarizations indicate the first phase of insulin release due to the exocytosis of docked and primed readily releasable granules (RRP), and the next eight depolarizations represent the second phase of insulin secretion from the reserve pool [39]. To identify the pancreatic  $\beta$ -cells in rodent, inactivation properties of  $\text{Na}^+$  channel were detected. The half-maximal inactivation of  $\text{Na}^+$  channels in  $\beta$ -cells is at  $\sim 78 \text{ mV}$ , whereas it's at  $\sim 40 \text{ mV}$  and  $\sim 20 \text{ mV}$  for  $\alpha$ -cells and  $\delta$ -cells, respectively [224]. However, this method does not apply to human islet cells, instead, cells bigger than  $9 \text{ pF}$  are considered to be  $\beta$ -cells [225].



# Results and Discussion

## Paper I and II

### **Upregulated Piezo1 expression in T2D islets**

RNA-sequencing (RNA-seq) data verifies the presence of PIEZO1 in human tissues including pancreatic islets and a similar expression pattern is also observed in a panel of mouse tissues by qPCR. More importantly, PIEZO1 expression is significantly higher in islets from T2D and diabetic *db/db* mice. A similar enhanced expression pattern of Piezo1 is also found in ageing transgenic Alzheimer's rats [226] and prostate cancer cell lines/tumor tissues [227]. Mechanical activation of Piezo1 results in development of pancreatitis [228] and exerts an important role in cardiac remodeling [229]. These suggest that upregulation of Piezo1 might be a risk/causative factor for T2D.

Immunostaining further confirms that expression of Piezo1 in single  $\alpha$ - and  $\beta$ -cells is comparable in both human and mouse islets, but interestingly with different localizations. Piezo1 is found in the cytosol and membrane area of  $\beta$ -cells, while in  $\alpha$ -cells the nuclear expression of Piezo1 is much more prominent. Under standard culture conditions (10 mM glucose),  $\alpha$ -cells exhibit more nuclear Piezo1 than the  $\beta$ -cells. This is probably related to the opposite physiological triggering of  $\alpha$ - and  $\beta$ -cell activity. For instance, at high glucose, glucagon secretion is suppressed while insulin is activated.

### **Hyperglycemia induces translocation of Piezo1 into the nucleus**

Since Piezo1 is present in both human and mouse  $\beta$ -cells, it prompted us to test whether elevated glucose affected its intracellular distribution. The data in dispersed/intact islet demonstrate that exposing  $\beta$ -cells to high glucose promotes the intracellular translocation of PIEZO1 from the cytosol and membrane into the nucleus.

The proportion of Piezo1 in the nucleus of islet  $\beta$ -cells in hyperglycemic/diabetic *db/db* mice (fed plasma glucose: >25 mM) is significantly higher than in  $\beta$ -cells from normoglycaemic control mice. Interestingly, this nuclear Piezo1 can be

relocated to the cytosol and membrane area after incubation in normal glucose. The intracellular distribution of PIEZO1 in  $\beta$ -cells from non-diabetic and T2D donors were also compared, but no significant difference was observed. Presumably, the diagnosed diabetic donors were well-treated with appropriate hypoglycemic medication, resulting in near-normoglycemia, which might affect the results. Ideally, islets from undiagnosed T2D donors with high HbA1c should be the critical comparable group versus healthy donors, to correctly assess the real distribution of Piezo1 under hyperglycemia. This suggests that Piezo1 distribution is glucose-dependent. As a mechanosensitive channel, a decreased amount of membrane Piezo1 could affect the proper function for ion passage, whereas the role of internalized Piezo1 is worthy of further exploration. Another piece of evidence from epithelial cells also shows that Piezo1 redistributes to the area close to the nucleus from the cytosol when cells are in dense regions [230]. Altogether, these findings demonstrate that localization of Piezo1 is under metabolic regulation and also raise interesting possibilities that  $\beta$ -cells respond to various environmental stimuli by translocation of Piezo1.

To determine which domain of Piezo1 controls the intracellular trafficking, mouse Piezo1 fragments from the pore-forming C-terminal (aa2189-2547) were overexpressed in INS-1 832/13 cells and the cells were challenged with different concentrations of glucose. We find that Piezo1 aa2458-2547-GFP (the inner helix of the pore) exhibits redistribution from nuclear to cytosol in response to high glucose while no translocation for Piezo1 aa2189-2547-GFP (comprising the entity of central pore) or aa2189-2458-GFP (corresponding to the outer helix of the pore). A similar phenomenon, that the nucleus localization of C-terminal (1592 to 2521) translocates to the cytosol and surface area, is also observed when co-expressed with the N-terminal (1-1591) of Piezo1 [231]. Taken together, the C-terminal inner helix part of Piezo1 is required for intracellular trafficking. However, we acknowledge that the exact sites responsible for sensing the metabolic state and translocation to the nucleus remain to be identified.

### **Piezo1 is important for swelling-induced insulin secretion**

The passage of cations, including  $\text{Ca}^{2+}$ , through Piezo1 is associated with membrane depolarization [90, 107]. As expected, hypotonic swelling-induced  $\text{Ca}^{2+}$  signaling and membrane potential is inhibited by the Piezo antagonist GsMTx4 in INS-1 832/13 cells. Low expression of Piezo2 in INS-1 832/13 cells, also in mouse and human  $\beta$ -cells [22, 23], points to the predominant importance of Piezo1 in mechanosensory-induced depolarization of the  $\beta$ -cell membrane. In addition, GsMTx4 abolishes hypotonic swelling-stimulated insulin secretion, collectively indicating the involvement of Piezo1 in this respect.

Pancreatic islets are richly vascularized and the blood flow exhibits great variation *in vivo* [232]. Piezo1 has been reported to be activated by shear stress [13, 25, 26]. We mimicked this in experimental settings and shear stress indeed induces insulin secretion, but it is persisted by the application of GsMTx4. According to the activation mode of Piezo1 [99-101, 114] by membrane tension, hypotonicity-induced swelling and shear stress-driven forces provide different kinds of lateral friction for stimulating Piezo1, which might represent distinct pathways. Collectively, these data demonstrate that whereas  $\beta$ -cells respond to both shear stress and hypotonicity with stimulation of insulin secretion, only the latter effect reflects activation of Piezo1. Together with other reports, we conclude that  $\beta$ -cells are mechanosensitive [69, 75, 233]. These findings indicate a novel pathway involving Piezo1 regulating mechanical forces-induced insulin release. This appears to function independently of VRAC [70, 75, 234] which has been suggested to associate with hypotonicity/glucose-induced insulin secretion.

### **Piezo1 controls cytosolic $\text{Ca}^{2+}$ homeostasis in $\beta$ -cells**

We next compared the effects of glucose and the non-metabolizable hexose mannitol (as an osmotic control) on  $[\text{Ca}^{2+}]_i$ . High glucose, but not mannitol, exerts a robust stimulatory effect of  $[\text{Ca}^{2+}]_i$  and silencing of *Piezo1* decreases this metabolic  $[\text{Ca}^{2+}]_i$  elevation. Importantly, the  $[\text{Ca}^{2+}]_i$  evoked by high extracellular  $\text{K}^+$  (70 mM) is unaffected by silencing *Piezo1*. The specific Piezo1 activator yoda1 [235] increases  $[\text{Ca}^{2+}]_i$  when applied at 2.8 mM glucose in primary human and rat  $\beta$ -cells. In contrast, GsMTx4 abolishes glucose-induced  $[\text{Ca}^{2+}]_i$  oscillations in both human and rat  $\beta$ -cells whilst not affecting the peak produced by high- $[\text{K}^+]_o$  depolarization. Furthermore, activation of Piezo1 by yoda1 depolarizes the  $\beta$ -cell membrane whereas silencing of *Piezo1* inhibited high glucose-induced depolarization. An abundance of reports has revealed the regulation of Piezo1 on  $\text{Ca}^{2+}$  homeostasis in insulin-secreting cell lines [113], urothelial cells [106], astrocytes [226], prostate cancer cell lines [227], cardiac fibroblasts [229], endothelial cells [236]. These support our findings that Piezo1 is particularly important for controlling  $\text{Ca}^{2+}$  signaling by sensing uptake and metabolism of glucose.

Shear stress has previously been reported to cause depolarization and activate VGCC in the adjacent vascular smooth muscle cells [26]. This suggests an additional effect on VGCC which is triggered by the mechanical stimuli-enhanced  $\beta$ -cell basal depolarization via Piezo1. RNA-seq and qPCR data demonstrate that *Piezo1* mRNA expression has either positive or negative correlations with  $\text{Ca}^{2+}$  channels. dSTORM super-resolution TIRF imaging reveals the physical association between PIEZO1 and Cav1.3. These primary data provides great information to verify our hypothesis but needs further confirmation. For example, which  $\text{Ca}^{2+}$  channel plays the predominant role in response to Piezo1-mediated depolarization requires careful validation.



## **Piezo1 is required for glucose-stimulated insulin secretion in $\beta$ -cells**

Next, the function of Piezo1 in insulin secretion was investigated. GsMTx4 abolishes glucose-stimulated insulin secretion in both human, rat islets and INS-1 832/13 cells. Pancreas perfusion also reveals the inhibitory effect of GsMTx4 on insulin secretion under quasi-physiological conditions. Silencing of *Piezo1* manifests a similar reduced effect on GSIS. However, *Piezo1* silencing does not affect high- $K^+$  induced insulin secretion which is in line with the  $[Ca^{2+}]_i$  imaging data.

The activation of Piezo1 by yoda1 dramatically increases glucose-stimulated insulin release. The closure of  $K_{ATP}$  channel is central in the insulin triggering pathway [42, 237, 238]. To study whether Piezo1 exerts via a  $K_{ATP}$  channel-independent action, the  $K_{ATP}$  channel opener diazoxide (DZX) was used for testing. The stimulatory effect of yoda1 at basal is abolished by DZX, while at high glucose, yoda1 retains a minor stimulatory effect in the presence of DZX. These findings suggest that Piezo1-activated insulin secretion can occur independently from the triggering pathway but can be markedly enhanced by a series of actions after glucose metabolism (e.g. depolarization after the closure of  $K_{ATP}$  channel). As expected, either DZX, yoda1 or the combination of the two have no effect on high  $K^+$ -stimulated insulin secretion, which demonstrates their action on glucose sensing in the  $\beta$ -cell. Hence, inhibition of  $K_{ATP}$  channel by glucose metabolism is required for Piezo1-mediated GSIS.

We also tested the effect of yoda1 *ex vivo* by pancreas perfusion. 0.01% DMSO was used as the solvent for yoda1 and that interfered with insulin secretion in the perfused pancreas. In control experiments, glucose stimulated insulin secretion for <3-fold. However, the stimulatory effect of glucose was ~7-fold when the experiment was repeated in the continuous presence of yoda1. It is notable that the effect of yoda1 was restricted to the 1st phase (t=12-16 min) glucose-induced insulin secretion with no stimulation observed during the 2nd phase (t=25-40 min).

SWELL1 has been indicated to sense glucose-induced cell swelling and mediate insulin secretion [75]. Piezo1 seems to operate in parallel with Swell1 and both of them contribute to the swelling-induced signaling pathway, since either silencing these genes alone or double knockdown has similar effects on hypotonicity-induced  $[Ca^{2+}]_i$  signaling. This indicates that there might be more than one system responding to the glucose-induced swelling and mediate insulin secretion.

## **Regulation of Piezo1 on global gene expression and hypotonicity-stimulated insulin secretion**

The shift of Piezo1 into nuclei under hyperglycemia suggests that Piezo1 might also play roles in gene transcription. To this end, mRNA-sequencing unravels the genes

regulated by *Piezo1*. 3300 genes in total are significantly differentially expressed, among which 1452 genes are downregulated and 1394 genes are upregulated after silencing *Piezo1*. Gene Ontology (GO) terms enrichment show that 58 genes in “regulation of intracellular transport” and 42 genes in “nucleocytoplasmic transport” are downregulated by silencing of *Piezo1*. These provide interesting candidates for further study of the mechanism for *Piezo1* redistribution under hyperglycemia in  $\beta$ -cells. More intriguingly, 68 genes involved in “positive regulation of secretion” are upregulated due to *Piezo1* silencing. Cocaine- and amphetamine-regulated transcript (CART) ranks in the top 1, the upregulation of mRNA expression of the top genes is verified by qPCR analysis.

To continue identifying the functions, *Piezo1* and/or *Cartpt* were silenced for measuring hypotonicity-stimulated insulin secretion (HSIS). Surprisingly, silencing of *Piezo1* dramatically increases HSIS which is opposite to the findings by *Piezo1* channel blocker GsMTx4. This effect of increased HSIS can be counteracted by keeping the low expression of *Cartpt* by double knockdown of *Piezo1* and *Cartpt*.

Intriguingly, the  $K_{ATP}$  channel opener diazoxide (DZX) eliminated HSIS in either non-targeting siRNA treated cells (si-Ctrl) or *Piezo1*-silenced cells indicating the involvement of  $K_{ATP}$  channel-closure mediated membrane depolarization in HSIS.

$Ca^{2+}$  imaging and membrane potential were performed to further demonstrate the mechanisms behind the increased HSIS after silencing of *Piezo1*. Hypotonicity-induced  $[Ca^{2+}]_i$  is significantly reduced by silencing of *Piezo1* which is in line with previous data. In contrast, hypotonicity stimulated-membrane depolarization is enhanced which might explain the increased HSIS after silencing of *Piezo1*. *Piezo1* knockdown results in secondary changes in gene expression, especially *Cartpt*. This might explain the discrepancy between GsMTx4 (merely block *Piezo1*) and silencing of *Piezo1*. Taken together, these results unequivocally demonstrate that hypotonic swelling-induced insulin secretion requires  $K_{ATP}$  channel-closure mediated membrane depolarization and also indicate that *Piezo1* possesses diverse functions other than as a mechanosensitive cation channel. The distinct effects of silencing *Piezo1* on GSIS and HSIS also suggest that HSIS follows different pathways from GSIS, for instance,  $Ca^{2+}$  is not a necessity for HSIS [239].

## Glucose homeostasis in $\beta$ -cell-specific *Piezo1* knockout mice

At this point we wanted to know the function of *Piezo1* *in vivo*. *Piezo1*-deficient embryos die at midgestation due to defects in blood flow activated vascular development [108]. To this end,  $\beta$ -cell-specific *Piezo1* knockout mice were generated by using RIP-Cre mice and floxed *Piezo1* mice. The littermates were genotyped, confirmed by qPCR, and single islet cell immunostaining. Collectively, all results pointed to successful generation of  $\beta$ -cell-specific *Piezo1* knockout mice.

Then, glucose utilization *in vivo* was tested by intraperitoneal glucose tolerance test (IPGTT) at different ages in male and female Cre<sup>+</sup> (control), Cre<sup>+</sup>.P<sub>1</sub><sup>ff</sup> (homozygote Piezo1 knockout) mice without prior fasting. Male Cre<sup>+</sup>.P<sub>1</sub><sup>ff</sup> mice at 5-8 weeks show a higher blood glucose post-IPGTT than the control mice. There is no difference between these groups of mice at 15 weeks. More intriguingly, homozygote knockout of Piezo1 lowers the blood glucose when the mice are older than 25 weeks and the blood glucose post-IPGTT tends to return to the basal more rapidly in the Cre<sup>+</sup>.P<sub>1</sub><sup>ff</sup> mice. Deletion of Piezo1 in female does not affect the blood glucose concentration before 15 weeks of age, however, the blood glucose is markedly reduced compared to the Cre<sup>+</sup> mice above 25 weeks.

### **Insulin secretion in $\beta$ -cell-specific *Piezo1* knockout mice**

To explain the phenotypes above, static incubations of isolated islets from male Cre<sup>+</sup>, Cre<sup>+</sup>.P<sub>1</sub><sup>ff</sup> mice for insulin secretion were performed at comparable ages as above. GSIS in young 7-8 weeks old male mice is impaired in Cre<sup>+</sup>.P<sub>1</sub><sup>ff</sup> mice. Both groups of 15-week old mice show a similar insulin-secreting capacity in response to high glucose. Interestingly, GSIS in the >22-week of age Cre<sup>+</sup>.P<sub>1</sub><sup>ff</sup> mice is remarkably increased. Taken together, these insulin secretion data perfectly echo the IPGTT results. *Piezo1* ablation in  $\beta$ -cells surprisingly appears to have an age-dependent effect *in vivo*. Knockout of *Piezo1* transiently impairs glucose tolerance and insulin secretion in young mice, which is in line with our data *in vitro*. In terms of blood glucose, control mice show slight glucose intolerance and a lowered insulin release upon glucose stimulation with increasing age, whereas lack of Piezo1 in  $\beta$ -cells in older mice results in better glucose utilization and an increased GSIS. These data demonstrate either bidirectional functions of Piezo1 at different ages or that other age-dependent factors compensate for *Piezo1* depletion in older mice. The RNA-seq data in *Piezo1*-silenced INS-1 832/13 cells might support the latter hypothesis. For example, silencing of *Piezo1* results in the upregulation of mRNA expression of 68 genes involved in “positive regulation of secretion” and the amphetamine-regulated transcript (CART) is within the top 1. Reports show that CART is expressed in the majority of rat islet cell types (except ghrelin cells) within a period of two weeks after birth, CART expression later on is restricted to somatostatin cells [240]. Endogenous  $\beta$ -cell CART promotes both expression and secretion of insulin through the regulation of exocytotic machinery and key  $\beta$ -cell transcription factors [241]. Therefore, we hypothesize that  $\beta$ -cell-specific knockout of *Piezo1* might upregulate the expression of Cart in  $\beta$ -cells by age, this compensatory effect by Cart increases functional  $\beta$ -cell mass and long-term insulin secretion [242]. This hypothesis can be verified by testing the expression of those Piezo1-upregulated genes including Cart and  $\beta$ -cell proliferation in the knockout mice.

Deletion of the mechanosensitive channel Piezo1, as expected, reduces the peak response of hypotonic swelling-induced insulin secretion compared to control mice,

and also shows a tendency for decreased accumulated insulin secretion. The reduced hypotonicity-induced  $\text{Ca}^{2+}$  signaling after silencing of *Piezo1* *in vitro* might provide an explanation, but it deserves further investigation.

### **Electrical activity and calcium homeostasis in $\beta$ -cell-specific *Piezo1* knockout mice**

The previous data point to silencing of *Piezo1* or activation of *Piezo1* by yoda1 in INS-1 832/13 inhibits or induces glucose-induced membrane potential, respectively. To further study the possible changes in glucose-stimulated electrical activity after deletion of *Piezo1* in  $\beta$ -cells, the membrane potential in intact pancreatic islets was recorded during perfusion with increasing glucose concentrations from 5 mM to 16.7 mM. The islets were isolated from young mice (age 5-7 weeks): Large cells ( $> 8$  pF) without  $\text{Na}^+$  currents were categorized as  $\beta$ -cells. Strong depolarizing oscillations upon acute high glucose stimulation were observed in  $\text{Cre}^+$  mouse islet  $\beta$ -cells, whereas the electrical activity in *Piezo1*-depleted pancreatic  $\beta$ -cells was dramatically reduced. However, membrane depolarization caused by the  $\text{K}_{\text{ATP}}$  channel inhibitor tolbutamide was less influenced by the ablation of *Piezo1*, which is in line with our previous data. These results demonstrate that *Piezo1* is required for  $\beta$ -cell membrane depolarization, and also suggest that voltage-gated  $\text{Ca}^{2+}$  channel mediated  $\text{Ca}^{2+}$  currents are downstream effects of *Piezo1* activation.

As expected, high glucose-stimulated  $\text{Ca}^{2+}$  concentrations from dispersed  $\text{Cre}^+.\text{P}_1^{\text{ff}}$  mouse (15 weeks old) islet are decreased compared to the control mice. Single  $\beta$ -cell under perfusion was selected for  $[\text{Ca}^{2+}]_i$  analysis, demonstrating that  $\text{Ca}^{2+}$  signaling per se upon stimulation is reduced due to the deletion of *Piezo1*. Together with the data *in vitro*, these indicate the importance of *Piezo1* in intracellular  $\text{Ca}^{2+}$  handling.

Surprisingly,  $\beta$ -cells from  $\text{Cre}^+.\text{P}_1^{\text{ff}}$  mice respond to yoda1 the same extent as the  $\text{Cre}^+$  mice. This may be due to the complicated structure and size of the *Piezo1* protein (51 exons). A frameshift in the *Piezo1* gene after deletion of exons 20-23, located in the mechanosensitive part of *Piezo1*, might lead to a folded protein product which has a similar structure to the C-terminal of *Piezo1* comprising the yoda1 binding site, as previously suggested [243]. An alternative explanation might be that yoda1 also activates Trpv4-dependent  $\text{Ca}^{2+}$  signaling [244], which requires further investigation to be resolved.

## Highlights

1. Expression of the mechanosensitive channel Piezo1 is upregulated in T2D and shows heterogeneous localization in pancreatic  $\alpha$ - and  $\beta$ -cells.
2. Cytosolic and membrane-localized Piezo1 in healthy pancreatic  $\beta$ -cells translocate to the nucleus under hyperglycemia, while the resultant nuclear Piezo1 is reversible by treatment in standard glucose concentration.
3. Piezo1 is involved in hypotonic swelling-induced depolarization in  $\beta$ -cells and mediates mechanical force-stimulated insulin secretion.
4. Piezo1 is important for glucose-stimulated  $\text{Ca}^{2+}$  signaling, membrane depolarization and GSIS.
5. Piezo1 controls large gene networks with, particularly Cocaine- and Amphetamine-Regulated Transcript (CART) and regulates hypotonic swelling-induced depolarization and insulin secretion.
6.  $\beta$ -cell specific *Piezo1* knockout male mice show an age-dependent effect on glucose utilization *in vivo* and GSIS *ex vivo*.

## Paper III

### **Tcf7l2 controls expression of *Cacna2d1*/ $\alpha 2\delta$ -1**

TCF7L2 possesses the strongest genetic risk for T2D [194-196]. RNA-seq data indicates that one of the targeting genes by Tcf7l2 is the calcium channel subunit  $\alpha 2\delta$ -1/*Cacna2d1* [14]. *Tcf7l2* silencing in INS-1 832/13 cells and rat islets results in a significant downregulation of the mRNA expression as well as the protein level of *Cacna2d1*/ $\alpha 2\delta$ -1. The subunit  $\alpha 2\delta$ -1 is primarily found in brain, heart and skeletal muscle [245] and here we confirm the presence of  $\alpha 2\delta$ -1 in insulin-secreting cell lines and pancreatic islets.  $\alpha 2\delta$ -1 displays a predominant expression in islets as compared to the other  $\alpha 2\delta$  subtypes [246].

### **Silencing of *Cacna2d1* prevents trafficking of Cav1.2 to the plasma membrane and retains it in recycling endosomes**

It has been well studied that  $\alpha 2\delta$ -subunits regulate the trafficking of Cav $\alpha$ 1-subunit to the plasma membrane (PM) in *Xenopus* oocytes and brain [140, 141, 247], but not yet in pancreatic cells. Pancreatic  $\beta$ -cells possess calcium channels including Cav1.2, Cav1.3, Cav2.1, Cav2.2, Cav2.3 and Cav3.1 [125]. Half of the whole  $\text{Ca}^{2+}$  currents are conducted by the L-type calcium channels (Cav1.2 and Cav1.3) [120].

Cav1.2 is considered the major subtype of L-type  $\text{Ca}^{2+}$ -channels in mouse  $\beta$ -cells [124]. Therefore, we checked the expression and localization of Cav1.2 after silencing of *Cacna2d1*. However, neither mRNA expression nor protein level of Cav1.2 is affected by the deficiency of *Cacna2d1*.

Since resident proteins are transported via sophisticatedly regulated pathways [248], we attempt to study the effect of  $\alpha 2\delta$ -1 on Cav1.2 cellular distribution. The L-type  $\text{Ca}^{2+}$  channel  $\alpha$ -subunit Cav1.2 is reported to be recycling between Rab11-recycling endosomes and PM [249, 250]. Therefore, we tested whether  $\alpha 2\delta$ -1 influenced the trafficking of Cav1.2. As expected, the PM-located ( $\text{Na}^+/\text{K}^+$ -ATPase as the marker) Cav1.2 is significantly reduced and the amount in the recycling endosomes (Rab11 as the marker) is accordingly increased in *Cacna2d1*-silenced cells. Furthermore, overexpression of  $\alpha 2\delta$ -1 induces the PM expression of Cav1.2. These findings indicate that  $\alpha 2\delta$ -1 is responsible for the trafficking of Cav1.2 to the PM in  $\beta$ -cells. Regarding the regulation of Tcf712 on  $\alpha 2\delta$ -1, the effect of Tcf712 on translocation of Cav1.2 was also tested, but the effects were inconsistent. Silencing of *Tcf712* fails to decrease the plasma membrane localization of Cav1.2. The indirect effect of Tcf712 on PM expression of Cav1.2 might be compensated by other target genes, the identity of which are uncertain at this point.

### **Silencing of *Cacna2d1* affects $\text{Ca}^{2+}$ signaling and exocytosis**

We then investigated whether changing the PM expression of Cav1.2 by interfering with  $\alpha 2\delta$ -1 can affect  $\text{Ca}^{2+}$  signaling. Silencing of *Cacna2d1* leads to a significant drop of both depolarization-evoked and glucose-stimulated increases in  $[\text{Ca}^{2+}]_i$ ; compared to control.

The drug gabapentin (GBP) is used clinically as an anti-epileptic treatment. The mechanism of action involves inhibition of  $\alpha 2\delta$  subunits. As previously reported, long-term treatment (>24 h) with GBP reduces  $\text{Ca}^{2+}$  currents in dorsal root ganglion (DRG) neurons [251]. In the present study, pharmacological inhibition of  $\alpha 2\delta$  subunits by GBP also results in markedly reduced  $\text{K}^+$ -stimulated  $[\text{Ca}^{2+}]_i$  peaks in INS-1 832/13 cells. In line with this finding, both *Cacna2d1*-silencing or GBP treatment also decrease whole-cell  $\text{Ca}^{2+}$  currents in mouse islet  $\beta$ -cells. Clusters of Cav1.2 channels in COS1 cells can only be formed in the PM and manifest as functional voltage-gated channels when  $\beta$ - and  $\alpha 2\delta$ -subunits are fully assembled [252]. Unlike the  $\beta$ -subunits,  $\alpha 2\delta$  subunits affect both trafficking of Cav1.2 and Cav1.2-modulated  $\text{Ca}^{2+}$  currents [141]. Another intriguing observation suggests that Cav channel localization is important for the serious neurodegenerative disorder Huntington's disease. It has been suggested that Cav1.2 localization in the PM is regulated by the huntingtin-associated protein 1 (Hap1). The Hap1 protein is also present in  $\beta$ -cells and is essential for  $\text{Ca}^{2+}$  influx and insulin secretion [253]. Protein kinase C (PKC) also serves as a regulator for enhancing PM expression of Cav1.2

and by this mechanism facilitates macroscopic currents in a murine cardiomyocyte cell line (HL-1 cells) [254]. Hence, trafficking of Cav1.2 to PM is tightly controlled by various signalling pathways. Our data provide significant input in this respect in pancreatic  $\beta$ -cells.

Furthermore, our data corroborate previous reports to the effect that silencing of the diabetes gene *Tcf7l2* reduces  $[Ca^{2+}]_i$  signalling evoked by either high  $K^+$ - or glucose. We conclude that Cav1.2 is modulated by  $\alpha 2\delta$ -1 [141, 252] and  $\alpha 2\delta$ -1 is only one of the multiple downstream targets of *Tcf7l2*, whereby the diabetes gene can regulate voltage-gated  $Ca^{2+}$  influx in  $\beta$ -cells.

We finally explored the effects of  $\alpha 2\delta$ -1/*Tcf7l2* on GSIS in which  $Ca^{2+}$  is the major triggering factor [39, 42]. As hypothesized, silencing of *Cacna2d1* significantly reduces GSIS and silencing of *Tcf7l2* even more so. However, double knockdown of both genes had the strongest effect on reducing GSIS. This might indicate that other target genes of *Tcf7l2* (e.g. *ISL1*, *MAFA*, and *PDX1*) are involved [14].

Much to our surprise, treatment of GBP fails to influence insulin secretion. The exocytosis rate in INS-1 832/13 cells is unaffected by addition of GBP, which excludes the possibility of a confounding action by GBP directly stimulating the exocytotic machinery. Several cases about severe hypoglycemia from GBP-treated diabetic and non-diabetic patients have been reported, which is suggestive of an additional insulinotropic effect of GBP [255]. Nevertheless, at present, we have failed to identify a reasonable explanation. We assume that other GBP-related biological pathways interfere and compensate for the inhibition of insulin secretion exerted via affecting  $\alpha 2\delta$  subunits.

### **Overexpression of $\alpha 2\delta$ -1 partially counteracts the effect of silencing *Tcf7l2* on $Ca^{2+}$ signaling**

To study whether the defect of *Tcf7l2* could be rescued by  $\alpha 2\delta$ -1, we overexpressed  $\alpha 2\delta$ -1 in *Tcf7l2*-silenced cells. The reduced high glucose-stimulated  $[Ca^{2+}]_i$  signalling by silencing *Tcf7l2* is significantly counteracted by overexpression of  $\alpha 2\delta$ -1. This probably can be attributed to favouring a PM localization of Cav1.2. Therefore, increasing expression or activity of  $\alpha 2\delta$ -1 is a means of counteracting the effects of dysfunctional *Tcf7l2* on  $Ca^{2+}$  signalling in the  $\beta$ -cell. Seemingly contradicting this,  $[Ca^{2+}]_i$  is not further increased after overexpression of  $\alpha 2\delta$ -1 in control cells. However, since the auxiliary subunits ( $\alpha 2\delta$ ,  $\beta$  and  $\gamma$ ) are associated with the  $\alpha 1$  subunits (Cav1 or Cav2) in a 1:1:1:1 ratio [127, 131], it is reasonable to assume that excess  $\alpha 2\delta$ -1 has no positive effect on Cav channels assembly.

Overexpression of  $\alpha 2\delta$ -1 stimulates both high  $K^+$ - and glucose-induced insulin secretion strongly, but it fails to improve the defective insulin secretion in *Tcf7l2*-silenced cells. How can this be explained? Deletion of *Tcf7l2* has been reported to

result in a reduction of genes controlling exocytosis [14]. This we confirmed in our own setup, and qPCR analysis verified that silencing of *Tcf7l2* downregulates three SNARE complex-related genes *Syt14*, *Stxbp1* and *Vamp2*. Likewise, silencing of *Cacna2d1* has similar effects on these genes except *Vamp2*. However, the downregulation of these genes by impaired *Tcf7l2* function can not be rescued by overexpressing  $\alpha 2\delta$ -1. This explains why  $\alpha 2\delta$ -1 fails to improve the impaired insulin secretion in *Tcf7l2*-silenced cells even though the  $\text{Ca}^{2+}$  signaling is normalized. Taken together, the complicated regulation of *Tcf7l2* on the exocytotic machinery can be partially counteracted by overexpression of  $\alpha 2\delta$ -1.

## Highlights

1. *Tcf7l2* controls mRNA and protein expression of the Cav channel auxiliary subunit *Cacna2d1*/ $\alpha 2\delta$ -1.
2. The subunit  $\alpha 2\delta$ -1 enhances the trafficking of Cav1.2 to PM, silencing of *Cacna2d1* results in Cav1.2 being retained in the recycling endosome.
3. Silencing of *Cacna2d1* reduces both high  $\text{K}^{+}$ - and glucose-induced  $\text{Ca}^{2+}$  signaling and impairs GSIS, whilst overexpression of  $\alpha 2\delta$ -1 increases insulin secretion.
4. Overexpression of  $\alpha 2\delta$ -1 improves the defective  $[\text{Ca}^{2+}]_i$  in *Tcf7l2*-silenced cells but fails to affect the reduced gene expression of *Syt14*, *Stxbp1*, thereby it cannot fully reverse the defects caused by *Tcf7l2* silencing.

## Paper IV

### Expression of Cav $\gamma 4$ is downregulated in islets in T2D

Cav $\alpha 2\delta$ ,  $\beta$ ,  $\gamma$  subunits are the three auxiliary components associated with the pore-forming Cav $\alpha 1$  subunits and among which,  $\alpha 2\delta$ ,  $\beta$  subunits are well studied to be pivotal for the trafficking of  $\alpha 1$  subunits [140, 164, 256]. However, the role of  $\gamma$  subunits remains largely elusive in pancreatic  $\beta$ -cells. Among the eight isoforms,  $\gamma 4$  subunit was selected due to the significantly reduced expression in hyperglycemic human donors. Similar observations were made in type 2 diabetic rat/mouse models: Goto-kakizaki (GK) rats and *db/db* mice, but no alteration is observed in type 1 diabetic Akita mice. The expression of  $\gamma 4$  is also decreased by high glucose or palmitate treatment that mimics the diabetic condition.  $\gamma 4$  appears to be distributed in the cytosolic and membrane area in human islet  $\beta$ -cells. Since  $\gamma 4$  is physically



associated with Cav1.2 channels [129], it makes sense that  $\gamma 4$  distribution is consistent with the Cav1.2 expression pattern in pancreatic  $\beta$ -cells [249, 257].

### **Cav $\gamma 4$ is required for GSIS and exocytosis**

The altered expression of  $\gamma 4$  subunit in T2D human islets suggested us to further investigate its function in insulin release. Silencing of *CACNG4/Cacng4* in islets from human or rats result in clear suppression of GSIS. In line with this, depolarization-evoked increases in cell capacitance, reflecting  $\beta$ -cell exocytosis, are significantly decreased in *Cacng4*-silenced rat islet  $\beta$ -cells. Notably, both the 1<sup>st</sup> and 2<sup>nd</sup> phases of exocytosis (representing discharge of the readily releasable, and reserve pool of insulin granules, respectively) are dramatically reduced due to knockdown of *Cacng4*. Conversely, overexpression of  $\gamma 4$  improves the perturbed GSIS in diabetic human or GK rat islets and upregulates exocytosis in GK rat islet  $\beta$ -cells.

The importance of  $\text{Ca}^{2+}$  in GSIS has been repeatedly emphasized above, as well as by others [39, 42]. Therefore, we further explored whether  $\gamma 4$  is involved in  $\beta$ -cell  $\text{Ca}^{2+}$  homeostasis. Intracellular  $\text{Ca}^{2+}$  concentrations under either high  $\text{K}^+$  or high glucose stimulation are remarkably lowered in *Cacng4*-silenced INS-1 832/13 cells. By contrast, silencing of the gene family member *Cacng5* had no such effects. To exclude the possibility of contribution of  $\text{Ca}^{2+}$  from intracellular stores (e.g. ER, endosomes and lysosomes) [151, 258], voltage-gated  $\text{Ca}^{2+}$  currents were measured by patch clamp. As expected, silencing of *Cacng4* significantly reduced whole-cell  $\text{Ca}^{2+}$  currents in rat  $\beta$ -cells and INS-1 832/13 cells. In contrast, overexpression of  $\gamma 4$  enhanced voltage-gated  $\text{Ca}^{2+}$  influx in non-diabetic/T2D human and Wistar/GK rat  $\beta$ -cells. Taken together, these results demonstrate that  $\gamma 4$  affects intracellular  $\text{Ca}^{2+}$  concentrations by controlling influx from the extracellular space.

### **Cav $\gamma 4$ controls L-type $\text{Ca}^{2+}$ channel expression**

To further study the specific pore-forming  $\alpha 1$  subunits involved in the  $\gamma 4$ -mediated  $\text{Ca}^{2+}$  influx, pharmacological inhibitors of  $\text{Ca}^{2+}$  channels were applied in  $\text{Ca}^{2+}$  currents measurements. Silencing of *Cacng4* fails to further reduce isradipine (L-type  $\text{Ca}^{2+}$  channel blocker)-inhibited  $\text{Ca}^{2+}$  currents but retains its suppressive effect on  $\text{Ca}^{2+}$  influx in the presence of a cocktail of non-L-type  $\text{Ca}^{2+}$  channel inhibitors. This strongly suggests the involvement of L-type  $\text{Ca}^{2+}$  channels. Abundant results from RNA-seq analyses, qPCR and immunoblotting reveal that  $\gamma 4$  positively regulates the expression of Cav1.2 and Cav1.3 (two of the main L-type  $\text{Ca}^{2+}$  channels in  $\beta$ -cells [120, 124]). Moreover,  $\gamma 4$  physically associates with Cav1.3 while we failed to achieve evidence for direct interaction between  $\gamma 4$  and Cav1.2.

However, such association between  $\gamma 4$  and Cav1.2 has been verified in HEK293 cells, in which Cav1.2 currents activation/inactivation are differentially modulated by  $\gamma 4$  in the presence/absence of  $\alpha 2\delta$ -1 and  $\beta 2$  subunits [129]. Cav1.2 and Cav1.3 are firmly established as the main L-type channels regulating insulin secretion in rodent  $\beta$ -cells. Furthermore, their expression levels affect glycemic status in both human and mice [120, 126, 259]. Cav $\gamma 4$  has no correlations with the other two L-type  $\text{Ca}^{2+}$  channels, Cav1.1 and Cav1.4, which is consistent with these two channels being important in skeletal muscle and retina, but not in pancreatic islet  $\beta$ -cells [116, 125].

Notably, silencing of *Cacng4* also downregulates  $\alpha 2\delta$ -1 expression which modulates the trafficking of Cav1.2 to PM in  $\beta$ -cells [257], this provides an alternative means of  $\alpha 2\delta$ -1 regulation other than Tcf712. Moreover, it points to  $\gamma 4$  being capable of altering PM expression of Cav1.2 which is critical for Cav1.2  $\text{Ca}^{2+}$  currents [257, 260].

Taken together, all the evidence above suggests that  $\gamma 4$  manifests its role in  $\text{Ca}^{2+}$  influx and GSIS via the regulation of L-type  $\text{Ca}^{2+}$  channel expression (Cav1.2 and Cav1.3). The other auxiliary subunit  $\alpha 2\delta$ -1 is shown to control Cav1.2 trafficking and to influence the  $\beta$ -cell stimulus-secretion coupling pathway in Paper III. These findings identify additional mechanisms for the auxiliary subunits and clarify how they affect  $\beta$ -cell function.

## **Cav $\gamma 4$ is regulated by the transcription factor MafA**

To fully understand the regulatory pathway involving  $\gamma 4$ , the upstream regulator of  $\gamma 4$  was next explored. Microarray analysis of human islet transcription factors (TFs) provides a list of TFs that correlate with  $\gamma 4$ . The  $\beta$ -cell maturation marker MafA [175-177] was confirmed by qPCR and immunoblotting as one of the positive controller candidates of  $\gamma 4$ . MafA mediates the expression of  $\gamma 4$  by directly binding to its promoter and  $\beta$ -cell specific MafA ablation in mice (MafA $^{\Delta\beta\text{cell}}$ ) results in a strong reduction of  $\gamma 4$ . Furthermore, overexpression of  $\gamma 4$  in MafA $^{\Delta\beta\text{cell}}$  islets improves  $\text{Ca}^{2+}$  influx and insulin exocytosis possibly via the rescued expression of Cav1.2 and Cav1.3. The L-type  $\text{Ca}^{2+}$  channel blocker (isradipine) and activator (Bay K) fail to exert their expected actions in modulating  $\text{Ca}^{2+}$  currents and  $[\text{Ca}^{2+}]_i$  in  $\beta$ -cells from MafA $^{\Delta\beta\text{cell}}$  islets, which is reminiscent of the findings in *Cacng4*-silenced cells. Therefore, we conclude that Cav $\gamma 4$  is part of the MafA regulatory pathway and determines normal  $\beta$ -cell function.

$\beta$ -cell viability remains unchanged in *Cacng4*-silenced cells compared to control cells, as evidenced by a series of apoptosis and proliferation assays (Cleaved Caspase-3 [261, 262] and P21 [263]). Interestingly,  $\beta$ -cell dedifferentiation is

induced after silencing of *Cacng4*, as indicated by the  $\beta$ -cell dedifferentiation marker *Aldh1a3* (aldehyde dehydrogenase 1A3) [264]. In accord with this, *Aldh1a3* is suppressed by re-introducing  $\gamma 4$  in human islets. Several reports have shown that  $\gamma 4$  in brain is involved in neural differentiation [155, 265] and that  $\text{Ca}^{2+}$  signals control multiple developmental processes including differentiation [259, 266-268]. This clearly suggests that  $\gamma 4$  is required for maintaining the differentiation status of insulin-positive  $\beta$ -cells. Increasing evidence point to that it is dedifferentiation rather than  $\beta$ -cell death, causing  $\beta$ -cell failure in T2D [264, 269, 270]. Hence, restoring the differentiation of  $\beta$ -cells is a promising approach for treating T2D and  $\gamma 4$  may be the target in such therapy.

## Highlights

1. *Cav* $\gamma 4$  expression is downregulated in T2D patients and diabetic rodent models, as well as by *in vitro* glucotoxicity and lipotoxicity.
2. *Cav* $\gamma 4$  regulates  $\text{Ca}^{2+}$  influx and GSIS via controlling L-type  $\text{Ca}^{2+}$  channels expression in both human and rodent islets.
3. *Cav* $\gamma 4$  is directly controlled by  $\beta$ -cell transcription factor MafA.
4. *Cav* $\gamma 4$  is a potential target for rescuing dedifferentiated  $\beta$ -cells in T2D.

# Future perspectives

T2D is a complex disease resulting from the combined influence of genetic background, environmental impact and lifestyle. Understanding the linkage between the environmental input and gene regulatory pathways in insulin secretion from pancreatic  $\beta$ -cells is key for developing novel therapies to T2D. The *raison d'être* of the  $\beta$ -cell is the  $\text{Ca}^{2+}$ -dependent process of insulin exocytosis. This is according to the consensus view mediated by the closure of  $\text{K}_{\text{ATP}}$  channels and the activation of voltage-gated  $\text{Ca}^{2+}$  channels. This model has obvious shortcomings even though it has hypnotized the diabetes community for more than two decades. Studies in this thesis add novel data and knowledge to unravel the mechanism behind T2D development. Notably, the new findings of the involvement of mechanosensitive channel Piezo1 in regulating insulin release are revolutionary and will push on the old dogma. To completely understand the mechanosensing pathways, more detailed investigations are therefore required to pave ways for novel treatments of T2D.

Translocation of Piezo1 under different concentrations of glucose is of interest, but the function of the nuclear localization of Piezo1 in hyperglycemia requires further investigation. Importantly, it remains unclear whether Piezo1 distribution occurs before developing significant hyperglycemia or the other way around. The *db/db* mice show hyperinsulinemia at the age of 10 days and develop hyperglycemia at 8 weeks [271]. It is thus a good model to monitor Piezo1 distribution during the development of T2D. Knowing the cause-consequence link would clarify whether it is a good idea to prevent Piezo1 redistribution to the nucleus and thus rescue its normal function of mediating rhythmic action potential firing and insulin secretion.

Furthermore, we have provided initial clues to which regions of the Piezo1 protein are relevant for translocation, but a series of questions remain to be addressed: as one of the largest proteins, does Piezo1 need a chaperone for promoting translocation? Which is the domain harboring the translocation signal? Does it translocate by disintegrating into several parts or does the protein remain intact?

Piezo1 expression levels in neighboring glucagon-releasing  $\alpha$ -cells are comparable to those in  $\beta$ -cells. However,  $\alpha$ -cells show nuclear localization of Piezo1 when at rest under standard glucose concentration (10 mM), which is opposite to the situation in  $\beta$ -cells that reveal this pattern under conditions of intense stimulation. Does this indicate either an opposite function of Piezo1 in  $\alpha$ -cells or suggest the

channel actively balances glucagon and insulin secretion? This prompts the importance to further investigate the multifaceted roles of Piezo1 in pancreatic cells other than  $\beta$ -cells.

The generation of the  $\beta$ -cell specific *Piezo1* knockout mouse model is a milestone for studying Piezo1 *in vivo*. In young *Piezo1* KO mice, glucose tolerance and insulin secretion are impaired. Surprisingly, these parameters are improved with increasing age in *Piezo1* KO mice. To better understand the age-dependent effect of missing Piezo1, single-cell RNA sequencing in islets from different ages of *Piezo1* KO mice would provide a broad knowledge of genes regulated by Piezo1.

Given the upregulation of *Cartpt* after silencing of *Piezo1* in INS-1 832/13 cells, compensation of  $\beta$ -cell mass influencing factors might occur in *Piezo1* KO mice [242]. Therefore, examination of  $\beta$ -cell viability/proliferation and differentiation state would also be preferred in *Piezo1* KO mice. *Cart* (encoded by *Cartpt*) also facilitates the insulin exocytosis machinery [241], thus monitoring insulin secretion after regulating the expression of *Cart* (could also be other candidates as judged by the single-cell RNA-seq data) in  $\beta$ -cell *Piezo1*-deleted islets from different ages of mice is an alternative experiment to identify the functional factor behind the scenes.

We have demonstrated that  $\beta$ -cells are mechanosensitive and Piezo1 exerts a key role in sensing glucose-induced swelling to modulate  $\beta$ -cell function. This provides revolutionary new insights into how the  $\beta$ -cell works and how novel therapies against T2D could be developed. Recently, magnetic forces applied to nanoparticle-labeled Piezo1 has been revealed to efficiently facilitate Piezo1 activation *in vitro* [272]. We have previously used a dynamic magnetic field generator to control the movement of superparamagnetic nanoparticles (SPIONs) and this innovative approach reversibly evokes  $\text{Ca}^{2+}$  responses by mechanic stimuli in the insulin-secreting cell line [273]. Using external magnetic fields to control Piezo1 activity, and consequently insulin secretion, is a feasible and interesting approach. Ultrasound application has been confirmed to activate heterologous and endogenous Piezo1 to initiate  $\text{Ca}^{2+}$  influx in primary neurons [274]. These reports indicate novel ways to apply controlled mechanical force stimulation targeting Piezo1 in  $\beta$ -cells, and is a promising modality for restoring  $\beta$ -cell function and treating T2D. However, to make it possible, we need to solve a series of problems, for instance, identifying the electrical gating domain and the mechanosensing region of Piezo1 in  $\beta$ -cells, to optimize control of mechanical force, etc.

Finally, in this thesis, we identified that MafA regulates the auxiliary subunit  $\gamma 4$  and that the subunit is involved in controlling  $\beta$ -cell differentiation.  $\beta$ -cell failure caused by de-differentiation plays a vital role in the development of T2D [264, 269, 270]. Our data show that the expression of  $\gamma 4$  in islets from donors with T2D is significantly reduced. Therefore, increasing  $\gamma 4$  levels to restore the differentiation of  $\beta$ -cells is a promising approach for treating T2D. Nevertheless, we need to further

understand the function of  $\gamma 4$  in this respect, Cav $\gamma 4$  knockout mice [275] is a suitable model to investigate  $\beta$ -cell differentiation state and related  $\beta$ -cell function.

The findings in this thesis convincingly challenge the consensus model for glucose-stimulated insulin secretion and provide unequivocal evidence supporting a close to revolutionary view on the  $\beta$ -cell stimulus-secretion coupling involving the mechano-sensor Piezo1. The new concept of  $\beta$ -cell dedifferentiation in  $\beta$ -cell dysfunction is confirmed, and, surprisingly, the Cav channel subunit  $\gamma 4$  partakes in this reaction. Collectively, these findings open the door to several innovative approaches to finding new therapeutic strategies to combat T2D.



# Acknowledgment

This thesis is a fruit of all the support from my supervisors, colleagues, friends and family, otherwise, it would never happen.

First, I would like to express my sincere gratitude to my supervisor **Erik Renström**: Thank you for providing me the precious opportunity as a PhD student in the diabetes field. Thank you for your enlightenment and inspiration every time when I face difficulties. Thank you for your patience and encouragement which help me to stick on the journey of science. You are an extraordinary person with immense knowledge and an appealing personality. I am honored as a student of yours and I could not imagine having a better supervisor and mentor like you for my PhD study.

I truly appreciate my co-supervisor **Enming Zhang** for devoting a tremendous amount of time to train my academic thoughts, help me to design the experiments and systematically organize data. I benefit a lot from your enthusiasm and diligence for scientific research. Thank you for always inspire me to have high spirits and motivate me to proceed further. Thank you for caring for both me and my family.

My great thankfulness goes to two of the most important persons in our lab: **Anna-Maria V.Ramsay** and **Britt-Marie S Nilsson**. I acknowledge that all of us including me would feel insecure without you. **Anna-Maria**: your smile and sound make the lab warm like home. Millions of thanks to you for offering your kindly and timely help to solve my problems in either science or life. Your efficient working and fantastic skills in culturing cells boost the processing of my project. Thank you for teaching me the techniques and explaining the key steps in detail. Thank you for all the valuable advice and cheerful chats. **Britt-Marie**: Super appreciated for your countless help in my animal experiments. I enjoyed the days working with you. Thank you for all the nice conversations we had and the great recommendations about the beautiful sites and fun activities in Sweden. Thank you for giving me one of your favorite “mouse” which you have kept for years, it means a lot to me and I will carry it with all the fond memories with you.

My sincere gratitude to **Lena Eliasson** for your supportive dedication to our group works. Thank you for the fruitful discussions and insightful comments to proceed with my project. I benefit tremendously from learning your revision of the future perspectives of my thesis, which lifts my understanding of the project.



I would also like to thank **Thomas Thevenin** for leading me into the  $\alpha 2\delta 1$  project. Thank you for your patient guidance and encouragement. Thank you for teaching me to perform the experiments and analysis of data. It is you who helped me to lay a solid foundation for working independently.

I owe my earnest appreciation to **Patrik Rorsman** for the nice discussions and creative comments towards the Piezo1 project. Millions of thanks for devoting your precious time working on the manuscript. I am honored by having the opportunity to learn from you for scientific thinking and profound insights into the project.

I am grateful to **Albert Salehi** for always believe in me and tremendous support. Thank you for involving me in your fantastic VDAC project. I benefit from learning  $\text{Ca}^{2+}$  imaging for this project in the early days during my PhD study. I would also like to thank **Claes Wollheim** for the nice conversations in the retreat at the beginning of this year. I admire your kindness and immense knowledge.

Fortunately, I am blessed to have a group of talented and kind colleagues who are always willing to share their knowledge and offer a hand. It is enjoyable to work in such a super congenial and enthusiastic environment created by you: **Cheng Luan**, many thanks to you for all the professional inputs into my projects and generous help to me. This thesis is impossible without your support. I respect you as my bigger brother. **Mohammad Barghouth**, I am super lucky to have you as my team worker. Your endless help makes the Piezo1 project process productively and efficiently. I do not dare to imagine how tough it would be without you. Thank you for all the support and for being my true friend. **Abdulla Kazim**, thank you for being my office mate. Thank you for correcting my English writing of the  $\alpha 2\delta 1$  manuscript. **Pawel Buda**, thank you for sharing your fantastic skills and knowledge in western blotting and cellular fractionation. Thank you for all the nice chats. **Vini Nagaraj**, it was super nice to have you darling who can always fill the lab with laughter, thank you for the joyful chats. **Xiaoping Jiang**, thank you for your hard work on dSTORM super-resolution imaging which adds important input in my project. **Jones Ofori**, thank you for your greetings almost every day. Thank you for the nice discussions and supportive words. **Alexandros Karagiannopoulos**, thank you for the bioinformatic analysis of the RNA-seq data and the fruitful discussions. I would also like to express my appreciation to **Jonathan Esguerra**, **Anna Edlund**, **Vishal Salunkhe**, **Mototsugu Nagao**, **Annika Axelsson**, **Hannah Nenonen**, **Helena Malm**, **Israa Mohammed**, **Ruchi Jain**, **Gaurav Verma**, **Akira Asai**, **Ines Mollet**, **Thomas Reinbothe**, **Emily Tubbs**, **Maria Olofsson**, **Annie Chandy**, **Åsa Nilsson**, **Thomas Gunnarsson**, **Eitan Netanyahu**, **Daowei Yang** and **Rui Wu**, thank you for being friendly and helpful.

My special gratefulness to **Anna Wendt** for being the opponent of my half-time control, thanks for all the insightful and constructive questions. Thank you for your smile and encouragement which ease my stress. Thank you for all the nice chats and discussions. **Ulrika Krus**, thank you for the timely support for the information of

gene expression in human islets and also for allocating the islets. Thank you for organizing the Friday cake which brings everyone together.

I owe my heartfelt appreciation to my friends **Qing Liu** and **Yusheng Wang**. Thank you for all the caring suggestions for our life decisions. Thank you for everything you have done to help me and my family. I feel at ease and enjoyable since we have you as our neighbor. **Jiangming Sun** and **Li Zhu**, thank you for taking care of my little girl when I am not available, it really means a lot to me. Thank you for the cheerful trips we experienced. **Anita Alm, Feifei Du, Zhiyi Ding, Tian Yu, Esther Ding, Jianguo Jin, Huan Zhong, Jonas Tsang, Wanjun Wen, Henrik Nilsson, Canny Chiang, Haolin Liu, Wenying Gong, Ning Chen**, thank you for all the gatherings which make my life so much more wonderful and filled with joy. Thank you for always standing by me and caring for me.

I dedicate this book to my family with great thankfulness. To my **mother** and **father**, thank you for unconditionally trust me, encouraging me, caring for me and loving me. To my **mother in law**, thank you for helping me during my thesis writing and for understanding.

**Yongzhi Wang**, it is you who guided me into this challenging journey that fascinates me endlessly. Thank you for devoting a huge amount of time establishing the system of pancreas perfusion with me and conducting the experiment whenever it is required. Thank you for your love and all the unconditional support. Life would be gloomy without you. **Elin Wang**, my lovely girl, thank you for coming and you are the best present. It is you who make my life meaningful and joyful.



# References

1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. 2019: Brussels, Belgium.
2. Gregg, E.W., et al., *Changes in diabetes-related complications in the United States, 1990-2010*. N Engl J Med, 2014. **370**(16): p. 1514-23.
3. King, P., I. Peacock, and R. Donnelly, *The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes*. Br J Clin Pharmacol, 1999. **48**(5): p. 643-8.
4. White, M.G., J.A. Shaw, and R. Taylor, *Type 2 Diabetes: The Pathologic Basis of Reversible beta-Cell Dysfunction*. Diabetes Care, 2016. **39**(11): p. 2080-2088.
5. Da Silva Xavier, G., *The Cells of the Islets of Langerhans*. J Clin Med, 2018. **7**(3).
6. Weir, G.C. and S. Bonner-Weir, *Five stages of evolving beta-cell dysfunction during progression to diabetes*. Diabetes, 2004. **53 Suppl 3**: p. S16-21.
7. Chung, I.M., et al., *Insights on the current status and advancement of diabetes mellitus type 2 and to avert complications - An overview*. Biotechnology and Applied Biochemistry, 2019.
8. DeFronzo, R.A., R. Eldor, and M. Abdul-Ghani, *Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes*. Diabetes Care, 2013. **36 Suppl 2**: p. S127-38.
9. Russo, G.T., et al., *Factors associated with beta-cell dysfunction in type 2 diabetes: the BETADECLINE study*. PLoS One, 2014. **9**(10): p. e109702.
10. Ashcroft, F.M. and P. Rorsman, *Diabetes mellitus and the beta cell: the last ten years*. Cell, 2012. **148**(6): p. 1160-71.
11. Ling, C. and T. Ronn, *Epigenetics in Human Obesity and Type 2 Diabetes*. Cell Metab, 2019. **29**(5): p. 1028-1044.
12. Voight, B.F., et al., *Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis*. Nat Genet, 2010. **42**(7): p. 579-89.
13. Florez, J.C., *Newly identified loci highlight beta cell dysfunction as a key cause of type 2 diabetes: where are the insulin resistance genes?* Diabetologia, 2008. **51**(7): p. 1100-10.
14. Zhou, Y., et al., *TCF7L2 is a master regulator of insulin production and processing*. Hum Mol Genet, 2014. **23**(24): p. 6419-31.
15. Rosengren, A.H., et al., *Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes*. Science, 2010. **327**(5962): p. 217-20.

16. Aguilar-Bryan, L. and J. Bryan, *Molecular biology of adenosine triphosphate-sensitive potassium channels*. *Endocr Rev*, 1999. **20**(2): p. 101-35.
17. LeRoith, D., *Beta-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities*. *Am J Med*, 2002. **113 Suppl 6A**: p. 3S-11S.
18. Rosenfeld, L., *Insulin: discovery and controversy*. *Clin Chem*, 2002. **48**(12): p. 2270-88.
19. Sanger, F., *Chemistry of insulin; determination of the structure of insulin opens the way to greater understanding of life processes*. *Science*, 1959. **129**(3359): p. 1340-4.
20. Mayer, J.P., F. Zhang, and R.D. DiMarchi, *Insulin structure and function*. *Biopolymers*, 2007. **88**(5): p. 687-713.
21. Bellin, E.M.a.M.D., *Secretion of Insulin in Response to Diet and Hormones*. *Pancreapedia: Exocrine Pancreas Knowledge Base*, 2016.
22. Clark, P. and T. McDonald, *Diabetes Mellitus*, in *The Immunoassay Handbook*. 2013. p. 783-794.
23. Wahren, J., et al., *Role of C-peptide in human physiology*. *Am J Physiol Endocrinol Metab*, 2000. **278**(5): p. E759-68.
24. Hach, T., et al., *C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients*. *Exp Diabetes Res*, 2008. **2008**: p. 730594.
25. Johansson, B.L., B. Linde, and J. Wahren, *Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients*. *Diabetologia*, 1992. **35**(12): p. 1151-8.
26. Johansson, B.L. and J. Pernow, *C-peptide potentiates the vasoconstrictor effect of neuropeptide Y in insulin-dependent diabetic patients*. *Acta Physiol Scand*, 1999. **165**(1): p. 39-44.
27. Forst, T., et al., *Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus*. *J Clin Invest*, 1998. **101**(10): p. 2036-41.
28. Forst, T., et al., *Role of C-Peptide in the regulation of microvascular blood flow*. *Exp Diabetes Res*, 2008. **2008**: p. 176245.
29. Johansson, B.L., S. Sjoberg, and J. Wahren, *The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients*. *Diabetologia*, 1992. **35**(2): p. 121-8.
30. Sonksen, P.H., *Insulin, growth hormone and sport*. *J Endocrinol*, 2001. **170**(1): p. 13-25.
31. Tokarz, V.L., P.E. MacDonald, and A. Klip, *The cell biology of systemic insulin function*. *J Cell Biol*, 2018. **217**(7): p. 2273-2289.
32. Cherrington, A.D., et al., *Physiological consequences of phasic insulin release in the normal animal*. *Diabetes*, 2002. **51 Suppl 1**: p. S103-8.

33. Meier, J.J., J.D. Veldhuis, and P.C. Butler, *Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans*. *Diabetes*, 2005. **54**(6): p. 1649-56.
34. Lee, S.H., et al., *Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood*. *Mol Metab*, 2016. **5**(8): p. 589-601.
35. McCulloch, L.J., et al., *GLUT2 (SLC2A2) is not the principal glucose transporter in human pancreatic beta cells: implications for understanding genetic association signals at this locus*. *Mol Genet Metab*, 2011. **104**(4): p. 648-53.
36. De Vos, A., et al., *Human and rat beta cells differ in glucose transporter but not in glucokinase gene expression*. *J Clin Invest*, 1995. **96**(5): p. 2489-95.
37. Rorsman, P. and M. Braun, *Regulation of insulin secretion in human pancreatic islets*. *Annu Rev Physiol*, 2013. **75**: p. 155-79.
38. van de Bunt, M. and A.L. Gloyn, *A tale of two glucose transporters: how GLUT2 re-emerged as a contender for glucose transport into the human beta cell*. *Diabetologia*, 2012. **55**(9): p. 2312-5.
39. Rorsman, P. and E. Renstrom, *Insulin granule dynamics in pancreatic beta cells*. *Diabetologia*, 2003. **46**(8): p. 1029-45.
40. Lang, J., *Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion*. *Eur J Biochem*, 1999. **259**(1-2): p. 3-17.
41. Rorsman, P., et al., *The Cell Physiology of Biphasic Insulin Secretion*. *News Physiol Sci*, 2000. **15**: p. 72-77.
42. Rorsman, P. and F.M. Ashcroft, *Pancreatic beta-Cell Electrical Activity and Insulin Secretion: Of Mice and Men*. *Physiol Rev*, 2018. **98**(1): p. 117-214.
43. Henquin, J.C., *Triggering and amplifying pathways of regulation of insulin secretion by glucose*. *Diabetes*, 2000. **49**(11): p. 1751-60.
44. Henquin, J.C., et al., *Diazoxide and D600 inhibition of insulin release. Distinct mechanisms explain the specificity for different stimuli*. *Diabetes*, 1982. **31**(9): p. 776-83.
45. Shyng, S., T. Ferrigni, and C.G. Nichols, *Regulation of KATP channel activity by diazoxide and MgADP. Distinct functions of the two nucleotide binding folds of the sulfonylurea receptor*. *J Gen Physiol*, 1997. **110**(6): p. 643-54.
46. Gembal, M., P. Gilon, and J.C. Henquin, *Evidence that glucose can control insulin release independently from its action on ATP-sensitive K<sup>+</sup> channels in mouse B cells*. *J Clin Invest*, 1992. **89**(4): p. 1288-95.
47. Gembal, M., et al., *Mechanisms by which glucose can control insulin release independently from its action on adenosine triphosphate-sensitive K<sup>+</sup> channels in mouse B cells*. *J Clin Invest*, 1993. **91**(3): p. 871-80.
48. Straub, S.G., et al., *Glucose activates both K(ATP) channel-dependent and K(ATP) channel-independent signaling pathways in human islets*. *Diabetes*, 1998. **47**(5): p. 758-63.

49. Hohmeier, H.E., et al., *Isolation of INS-1-derived cell lines with robust ATP-sensitive K<sup>+</sup> channel-dependent and -independent glucose-stimulated insulin secretion*. *Diabetes*, 2000. **49**(3): p. 424-30.
50. Panten, U., et al., *Glucose both inhibits and stimulates insulin secretion from isolated pancreatic islets exposed to maximally effective concentrations of sulfonylureas*. *Naunyn Schmiedebergs Arch Pharmacol*, 1988. **338**(4): p. 459-62.
51. Best, L., A.P. Yates, and S. Tomlinson, *Stimulation of insulin secretion by glucose in the absence of diminished potassium (86Rb<sup>+</sup>) permeability*. *Biochem Pharmacol*, 1992. **43**(11): p. 2483-5.
52. Nenquin, M., et al., *Both triggering and amplifying pathways contribute to fuel-induced insulin secretion in the absence of sulfonylurea receptor-1 in pancreatic beta-cells*. *J Biol Chem*, 2004. **279**(31): p. 32316-24.
53. Ravier, M.A., et al., *Glucose controls cytosolic Ca<sup>2+</sup> and insulin secretion in mouse islets lacking adenosine triphosphate-sensitive K<sup>+</sup> channels owing to a knockout of the pore-forming subunit Kir6.2*. *Endocrinology*, 2009. **150**(1): p. 33-45.
54. Sato, Y., M. Anello, and J.C. Henquin, *Glucose regulation of insulin secretion independent of the opening or closure of adenosine triphosphate-sensitive K<sup>+</sup> channels in beta cells*. *Endocrinology*, 1999. **140**(5): p. 2252-7.
55. Jonas, J.C., P. Gilon, and J.C. Henquin, *Temporal and quantitative correlations between insulin secretion and stably elevated or oscillatory cytoplasmic Ca<sup>2+</sup> in mouse pancreatic beta-cells*. *Diabetes*, 1998. **47**(8): p. 1266-73.
56. Mourad, N.I., M. Nenquin, and J.C. Henquin, *Metabolic amplifying pathway increases both phases of insulin secretion independently of beta-cell actin microfilaments*. *Am J Physiol Cell Physiol*, 2010. **299**(2): p. C389-98.
57. Ivarsson, R., et al., *Redox control of exocytosis: regulatory role of NADPH, thioredoxin, and glutaredoxin*. *Diabetes*, 2005. **54**(7): p. 2132-42.
58. Goehring, I., et al., *Identification of an intracellular metabolic signature impairing beta cell function in the rat beta cell line INS-1E and human islets*. *Diabetologia*, 2011. **54**(10): p. 2584-94.
59. Santana, M.S., et al., *High frequency of diabetes and impaired fasting glucose in patients with glucose-6-phosphate dehydrogenase deficiency in the Western brazilian Amazon*. *Am J Trop Med Hyg*, 2014. **91**(1): p. 74-6.
60. Spegel, P., et al., *Time-resolved metabolomics analysis of beta-cells implicates the pentose phosphate pathway in the control of insulin release*. *Biochem J*, 2013. **450**(3): p. 595-605.
61. Cameron, W.D., et al., *Apollo-NADP(+): a spectrally tunable family of genetically encoded sensors for NADP(+)*. *Nat Methods*, 2016. **13**(4): p. 352-8.

62. Lewis, C.A., et al., *Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells*. Mol Cell, 2014. **55**(2): p. 253-63.
63. Fan, J., et al., *Quantitative flux analysis reveals folate-dependent NADPH production*. Nature, 2014. **510**(7504): p. 298-302.
64. Gooding, J.R., et al., *Adenylosuccinate Is an Insulin Secretagogue Derived from Glucose-Induced Purine Metabolism*. Cell Rep, 2015. **13**(1): p. 157-167.
65. Ferdaoussi, M., et al., *Isocitrate-to-SENPI signaling amplifies insulin secretion and rescues dysfunctional beta cells*. J Clin Invest, 2015. **125**(10): p. 3847-60.
66. Patterson, J.N., et al., *Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated insulin secretion*. J Biol Chem, 2014. **289**(19): p. 13335-46.
67. Kalwat, M.A. and M.H. Cobb, *Mechanisms of the amplifying pathway of insulin secretion in the beta cell*. Pharmacol Ther, 2017. **179**: p. 17-30.
68. Best, L. and P.D. Brown, *Studies of the mechanism of activation of the volume-regulated anion channel in rat pancreatic beta-cells*. J Membr Biol, 2009. **230**(2): p. 83-91.
69. Miley, H.E., et al., *Glucose-induced swelling in rat pancreatic beta-cells*. J Physiol, 1997. **504 ( Pt 1)**: p. 191-8.
70. Best, L., E.A. Shearer, and P.D. Brown, *A volume-activated anion conductance in insulin-secreting cells*. Pflugers Arch, 1996. **431**(3): p. 363-70.
71. Best, L., H.E. Miley, and A.P. Yates, *Activation of an anion conductance and beta-cell depolarization during hypotonically induced insulin release*. Exp Physiol, 1996. **81**(6): p. 927-33.
72. Best, L., *Study of a glucose-activated anion-selective channel in rat pancreatic beta-cells*. Pflugers Arch, 2002. **445**(1): p. 97-104.
73. Best, L., *Glucose-sensitive conductances in rat pancreatic beta-cells: contribution to electrical activity*. Biochim Biophys Acta, 2000. **1468**(1-2): p. 311-9.
74. Best, L., *Glucose and alpha-ketoisocaproate induce transient inward currents in rat pancreatic beta cells*. Diabetologia, 1997. **40**(1): p. 1-6.
75. Kang, C., et al., *SWELL1 is a glucose sensor regulating beta-cell excitability and systemic glycaemia*. Nat Commun, 2018. **9**(1): p. 367.
76. Kinard, T.A., et al., *Chloride channels regulate HIT cell volume but cannot fully account for swelling-induced insulin secretion*. Diabetes, 2001. **50**(5): p. 992-1003.
77. Straub, S.G., S. Daniel, and G.W. Sharp, *Hyposmotic shock stimulates insulin secretion by two distinct mechanisms. Studies with the betaHC9 cell*. Am J Physiol Endocrinol Metab, 2002. **282**(5): p. E1070-6.
78. Takii, M., et al., *Involvement of stretch-activated cation channels in hypotonically induced insulin secretion in rat pancreatic beta-cells*. Am J Physiol Cell Physiol, 2006. **291**(6): p. C1405-11.



79. Philippaert, K. and R. Vennekens, *The Role of TRP Channels in the Pancreatic Beta-Cell*, in *Neurobiology of TRP Channels*, nd and T.L.R. Emir, Editors. 2017: Boca Raton (FL). p. 229-250.
80. Marigo, V., et al., *TRPM4 impacts on Ca<sup>2+</sup> signals during agonist-induced insulin secretion in pancreatic beta-cells*. *Mol Cell Endocrinol*, 2009. **299**(2): p. 194-203.
81. Xu, X.Z., et al., *Regulation of melastatin, a TRP-related protein, through interaction with a cytoplasmic isoform*. *Proc Natl Acad Sci U S A*, 2001. **98**(19): p. 10692-7.
82. Gilon, P., et al., *Calcium signaling in pancreatic beta-cells in health and in Type 2 diabetes*. *Cell Calcium*, 2014. **56**(5): p. 340-61.
83. Liman, E.R., *A TRP channel contributes to insulin secretion by pancreatic beta-cells*. *Islets*, 2010. **2**(5): p. 331-3.
84. Colsoul, B., et al., *Loss of high-frequency glucose-induced Ca<sup>2+</sup> oscillations in pancreatic islets correlates with impaired glucose tolerance in Trpm5<sup>-/-</sup> mice*. *Proc Natl Acad Sci U S A*, 2010. **107**(11): p. 5208-13.
85. Nair, A.V., et al., *Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy*. *Proc Natl Acad Sci U S A*, 2012. **109**(28): p. 11324-9.
86. Yosida, M., et al., *Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion*. *Diabetes*, 2014. **63**(10): p. 3394-403.
87. Diaz-Garcia, C.M., et al., *Role for the TRPV1 channel in insulin secretion from pancreatic beta cells*. *J Membr Biol*, 2014. **247**(6): p. 479-91.
88. Lee, E., et al., *Transient receptor potential vanilloid type-1 channel regulates diet-induced obesity, insulin resistance, and leptin resistance*. *FASEB J*, 2015. **29**(8): p. 3182-92.
89. Sawatani, T., et al., *TRPV2 channels mediate insulin secretion induced by cell swelling in mouse pancreatic beta-cells*. *Am J Physiol Cell Physiol*, 2019. **316**(3): p. C434-C443.
90. Coste, B., et al., *Piezo1 and Piezo2 are essential components of distinct mechanically activated cation channels*. *Science*, 2010. **330**(6000): p. 55-60.
91. B.S. Barker, G.T.Y., C.H. Soubrane, G.J. Stephens, E.B. Stevens, M.K. Patel,, *Ion Channels*. Conn's Translational Neuroscience. 2017.
92. Catherine Litalien, P.B., *Molecular Mechanisms of Drug Actions: From Receptors to Effectors*, J.J.Z. Bradley P. Fuhrman, Editor. 2011. p. 1553-1568.
93. Lamothe, S.M. and S. Zhang, *Chapter Five - Ubiquitination of Ion Channels and Transporters*. *Prog Mol Biol Transl Sci*, 2016. **141**: p. 161-223.
94. Jacobson, D.A. and S.L. Shyng, *Ion Channels of the Islets in Type 2 Diabetes*. *J Mol Biol*, 2019.
95. Chalfie, M., *Neurosensory mechanotransduction*. *Nat Rev Mol Cell Biol*, 2009. **10**(1): p. 44-52.

96. Hamill, O.P. and B. Martinac, *Molecular basis of mechanotransduction in living cells*. *Physiol Rev*, 2001. **81**(2): p. 685-740.
97. Guharay, F. and F. Sachs, *Stretch-activated single ion channel currents in tissue-cultured embryonic chick skeletal muscle*. *J Physiol*, 1984. **352**: p. 685-701.
98. Coste, B., et al., *Piezo proteins are pore-forming subunits of mechanically activated channels*. *Nature*, 2012. **483**(7388): p. 176-81.
99. Zhao, Q., et al., *Ion Permeation and Mechanotransduction Mechanisms of Mechanosensitive Piezo Channels*. *Neuron*, 2016. **89**(6): p. 1248-1263.
100. Lin, Y.C., et al., *Force-induced conformational changes in PIEZO1*. *Nature*, 2019. **573**(7773): p. 230-234.
101. Ge, J., et al., *Architecture of the mammalian mechanosensitive Piezo1 channel*. *Nature*, 2015. **527**(7576): p. 64-9.
102. Coste, B., et al., *Piezo1 ion channel pore properties are dictated by C-terminal region*. *Nat Commun*, 2015. **6**: p. 7223.
103. Cox, C.D., et al., *Removal of the mechanoprotective influence of the cytoskeleton reveals PIEZO1 is gated by bilayer tension*. *Nat Commun*, 2016. **7**: p. 10366.
104. Haselwandter, C.A. and R. MacKinnon, *Piezo's membrane footprint and its contribution to mechanosensitivity*. *Elife*, 2018. **7**.
105. Bagriantsev, S.N., E.O. Gracheva, and P.G. Gallagher, *Piezo proteins: regulators of mechanosensation and other cellular processes*. *J Biol Chem*, 2014. **289**(46): p. 31673-81.
106. Miyamoto, T., et al., *Functional role for Piezo1 in stretch-evoked Ca(2)(+) influx and ATP release in urothelial cell cultures*. *J Biol Chem*, 2014. **289**(23): p. 16565-75.
107. Li, J., et al., *Piezo1 integration of vascular architecture with physiological force*. *Nature*, 2014. **515**(7526): p. 279-282.
108. Ranade, S.S., et al., *Piezo1, a mechanically activated ion channel, is required for vascular development in mice*. *Proc Natl Acad Sci U S A*, 2014. **111**(28): p. 10347-52.
109. Cahalan, S.M., et al., *Piezo1 links mechanical forces to red blood cell volume*. *Elife*, 2015. **4**.
110. Volkens, L., Y. Mechioukhi, and B. Coste, *Piezo channels: from structure to function*. *Pflugers Arch*, 2015. **467**(1): p. 95-9.
111. Albuissou, J., et al., *Dehydrated hereditary stomatocytosis linked to gain-of-function mutations in mechanically activated PIEZO1 ion channels*. *Nat Commun*, 2013. **4**: p. 1884.
112. Chen, P., et al., *Multiple nonglycemic genomic loci are newly associated with blood level of glycosylated hemoglobin in East Asians*. *Diabetes*, 2014. **63**(7): p. 2551-62.
113. Deivasikamani, V., et al., *Piezo1 channel activation mimics high glucose as a stimulator of insulin release*. *Sci Rep*, 2019. **9**(1): p. 16876.
114. Syeda, R., et al., *Piezo1 Channels Are Inherently Mechanosensitive*. *Cell Rep*, 2016. **17**(7): p. 1739-1746.

115. Yang, S.N. and P.O. Berggren, *Beta-cell Ca<sub>v</sub> channel regulation in physiology and pathophysiology*. Am J Physiol Endocrinol Metab, 2005. **288**(1): p. E16-28.
116. Catterall, W.A., *Structure and regulation of voltage-gated Ca<sub>2</sub><sup>+</sup> channels*. Annu Rev Cell Dev Biol, 2000. **16**: p. 521-55.
117. Nowycky, M.C., A.P. Fox, and R.W. Tsien, *Three types of neuronal calcium channel with different calcium agonist sensitivity*. Nature, 1985. **316**(6027): p. 440-3.
118. Mintz, I.M., M.E. Adams, and B.P. Bean, *P-type calcium channels in rat central and peripheral neurons*. Neuron, 1992. **9**(1): p. 85-95.
119. Piedras-Renteria, E.S. and R.W. Tsien, *Antisense oligonucleotides against alpha1E reduce R-type calcium currents in cerebellar granule cells*. Proc Natl Acad Sci U S A, 1998. **95**(13): p. 7760-5.
120. Schulla, V., et al., *Impaired insulin secretion and glucose tolerance in beta cell-selective Ca(v)1.2 Ca<sub>2</sub><sup>+</sup> channel null mice*. EMBO J, 2003. **22**(15): p. 3844-54.
121. Perez-Reyes, E., et al., *Molecular characterization of a neuronal low-voltage-activated T-type calcium channel*. Nature, 1998. **391**(6670): p. 896-900.
122. Perez-Reyes, E., *Molecular characterization of a novel family of low voltage-activated, T-type, calcium channels*. J Bioenerg Biomembr, 1998. **30**(4): p. 313-8.
123. Cribbs, L.L., et al., *Cloning and characterization of alpha1H from human heart, a member of the T-type Ca<sub>2</sub><sup>+</sup> channel gene family*. Circ Res, 1998. **83**(1): p. 103-9.
124. Rorsman, P., M. Braun, and Q. Zhang, *Regulation of calcium in pancreatic alpha- and beta-cells in health and disease*. Cell Calcium, 2012. **51**(3-4): p. 300-8.
125. Yang, S.N. and P.O. Berggren, *The role of voltage-gated calcium channels in pancreatic beta-cell physiology and pathophysiology*. Endocr Rev, 2006. **27**(6): p. 621-76.
126. Reinbothe, T.M., et al., *The human L-type calcium channel Cav1.3 regulates insulin release and polymorphisms in CACNA1D associate with type 2 diabetes*. Diabetologia, 2013. **56**(2): p. 340-9.
127. Dolphin, A.C., *Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology*. J Physiol, 2016. **594**(19): p. 5369-90.
128. Perez-Reyes, E., *Molecular physiology of low-voltage-activated t-type calcium channels*. Physiol Rev, 2003. **83**(1): p. 117-61.
129. Yang, L., et al., *Cardiac L-type calcium channel (Cav1.2) associates with gamma subunits*. FASEB J, 2011. **25**(3): p. 928-36.
130. Striessnig, J., et al., *L-type Ca(2+) channels in heart and brain*. Wiley Interdiscip Rev Membr Transp Signal, 2014. **3**(2): p. 15-38.

131. Campbell, K.P., A.T. Leung, and A.H. Sharp, *The biochemistry and molecular biology of the dihydropyridine-sensitive calcium channel*. Trends Neurosci, 1988. **11**(10): p. 425-30.
132. Kang, M.G., et al., *Biochemical and biophysical evidence for gamma 2 subunit association with neuronal voltage-activated Ca<sup>2+</sup> channels*. J Biol Chem, 2001. **276**(35): p. 32917-24.
133. Sharp, A.H., et al., *Biochemical and anatomical evidence for specialized voltage-dependent calcium channel gamma isoform expression in the epileptic and ataxic mouse, stargazer*. Neuroscience, 2001. **105**(3): p. 599-617.
134. Takahashi, M., et al., *Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle*. Proc Natl Acad Sci U S A, 1987. **84**(15): p. 5478-82.
135. Hosey, M.M., et al., *Photoaffinity labelling and phosphorylation of a 165 kilodalton peptide associated with dihydropyridine and phenylalkylamine-sensitive calcium channels*. Biochem Biophys Res Commun, 1987. **147**(3): p. 1137-45.
136. Leung, A.T., T. Imagawa, and K.P. Campbell, *Structural characterization of the 1,4-dihydropyridine receptor of the voltage-dependent Ca<sup>2+</sup> channel from rabbit skeletal muscle. Evidence for two distinct high molecular weight subunits*. J Biol Chem, 1987. **262**(17): p. 7943-6.
137. Striessnig, J., et al., *Photoaffinity labelling of the phenylalkylamine receptor of the skeletal muscle transverse-tubule calcium channel*. FEBS Lett, 1987. **212**(2): p. 247-53.
138. Ellis, S.B., et al., *Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel*. Science, 1988. **241**(4873): p. 1661-4.
139. Witcher, D.R., et al., *Subunit identification and reconstitution of the N-type Ca<sup>2+</sup> channel complex purified from brain*. Science, 1993. **261**(5120): p. 486-9.
140. Dolphin, A.C., *The alpha2delta subunits of voltage-gated calcium channels*. Biochim Biophys Acta, 2013. **1828**(7): p. 1541-9.
141. Shistik, E., et al., *Ca<sup>2+</sup> current enhancement by alpha 2/delta and beta subunits in Xenopus oocytes: contribution of changes in channel gating and alpha 1 protein level*. J Physiol, 1995. **489** ( Pt 1): p. 55-62.
142. Gurnett, C.A., M. De Waard, and K.P. Campbell, *Dual function of the voltage-dependent Ca<sup>2+</sup> channel alpha 2 delta subunit in current stimulation and subunit interaction*. Neuron, 1996. **16**(2): p. 431-40.
143. Felix, R., et al., *Dissection of functional domains of the voltage-dependent Ca<sup>2+</sup> channel alpha2delta subunit*. J Neurosci, 1997. **17**(18): p. 6884-91.
144. Wakamori, M., G. Mikala, and Y. Mori, *Auxiliary subunits operate as a molecular switch in determining gating behaviour of the unitary N-type Ca<sup>2+</sup> channel current in Xenopus oocytes*. J Physiol, 1999. **517** ( Pt 3): p. 659-72.

145. Davies, A., et al., *The alpha2delta subunits of voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for function.* Proc Natl Acad Sci U S A, 2010. **107**(4): p. 1654-9.
146. Cassidy, J.S., et al., *Functional exofacially tagged N-type calcium channels elucidate the interaction with auxiliary alpha2delta-1 subunits.* Proc Natl Acad Sci U S A, 2014. **111**(24): p. 8979-84.
147. Hoppa, M.B., et al., *alpha2delta expression sets presynaptic calcium channel abundance and release probability.* Nature, 2012. **486**(7401): p. 122-5.
148. Mastrolia, V., et al., *Loss of alpha2delta-1 Calcium Channel Subunit Function Increases the Susceptibility for Diabetes.* Diabetes, 2017. **66**(4): p. 897-907.
149. Burgess, D.L., et al., *A cluster of three novel Ca<sup>2+</sup> channel gamma subunit genes on chromosome 19q13.4: evolution and expression profile of the gamma subunit gene family.* Genomics, 2001. **71**(3): p. 339-50.
150. Chu, P.J., H.M. Robertson, and P.M. Best, *Calcium channel gamma subunits provide insights into the evolution of this gene family.* Gene, 2001. **280**(1-2): p. 37-48.
151. Chen, R.S., et al., *Calcium channel gamma subunits: a functionally diverse protein family.* Cell Biochem Biophys, 2007. **47**(2): p. 178-86.
152. Black, J.L., 3rd, *The voltage-gated calcium channel gamma subunits: a review of the literature.* J Bioenerg Biomembr, 2003. **35**(6): p. 649-60.
153. Hastoy, B., et al., *Electrophysiological properties of human beta-cell lines EndoC-betaH1 and -betaH2 conform with human beta-cells.* Sci Rep, 2018. **8**(1): p. 16994.
154. Howarth, F.C., et al., *The Pattern of mRNA Expression Is Changed in Sinoatrial Node from Goto-Kakizaki Type 2 Diabetic Rat Heart.* J Diabetes Res, 2018. **2018**: p. 8454078.
155. Kious, B.M., et al., *Identification and characterization of a calcium channel gamma subunit expressed in differentiating neurons and myoblasts.* Dev Biol, 2002. **243**(2): p. 249-59.
156. Klugbauer, N., et al., *A family of gamma-like calcium channel subunits.* FEBS Lett, 2000. **470**(2): p. 189-97.
157. Kasai, H., N. Takahashi, and H. Tokumaru, *Distinct initial SNARE configurations underlying the diversity of exocytosis.* Physiol Rev, 2012. **92**(4): p. 1915-64.
158. Sudhof, T.C., *Neurotransmitter release: the last millisecond in the life of a synaptic vesicle.* Neuron, 2013. **80**(3): p. 675-90.
159. Sudhof, T.C., *The presynaptic active zone.* Neuron, 2012. **75**(1): p. 11-25.
160. Sudhof, T.C. and J.E. Rothman, *Membrane fusion: grappling with SNARE and SM proteins.* Science, 2009. **323**(5913): p. 474-7.
161. Gaisano, H.Y., *Here come the newcomer granules, better late than never.* Trends Endocrinol Metab, 2014. **25**(8): p. 381-8.

162. Gaisano, H.Y., *Recent new insights into the role of SNARE and associated proteins in insulin granule exocytosis*. *Diabetes Obes Metab*, 2017. **19 Suppl 1**: p. 115-123.
163. Nagamatsu, S., et al., *Decreased expression of t-SNARE, syntaxin 1, and SNAP-25 in pancreatic beta-cells is involved in impaired insulin secretion from diabetic GK rat islets: restoration of decreased t-SNARE proteins improves impaired insulin secretion*. *Diabetes*, 1999. **48**(12): p. 2367-73.
164. Gaisano, H.Y., et al., *Abnormal expression of pancreatic islet exocytotic soluble N-ethylmaleimide-sensitive factor attachment protein receptors in Goto-Kakizaki rats is partially restored by phlorizin treatment and accentuated by high glucose treatment*. *Endocrinology*, 2002. **143**(11): p. 4218-26.
165. Ostenson, C.G., et al., *Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients*. *Diabetes*, 2006. **55**(2): p. 435-40.
166. Dubois, M., et al., *Glucotoxicity inhibits late steps of insulin exocytosis*. *Endocrinology*, 2007. **148**(4): p. 1605-14.
167. Gandasi, N.R. and S. Barg, *Contact-induced clustering of syntaxin and munc18 docks secretory granules at the exocytosis site*. *Nat Commun*, 2014. **5**: p. 3914.
168. Liang, T., et al., *New Roles of Syntaxin-1A in Insulin Granule Exocytosis and Replenishment*. *J Biol Chem*, 2017. **292**(6): p. 2203-2216.
169. Andersson, S.A., et al., *Reduced insulin secretion correlates with decreased expression of exocytotic genes in pancreatic islets from patients with type 2 diabetes*. *Mol Cell Endocrinol*, 2012. **364**(1-2): p. 36-45.
170. Salinno, C., et al., *beta-Cell Maturation and Identity in Health and Disease*. *Int J Mol Sci*, 2019. **20**(21).
171. Bensellam, M., J.C. Jonas, and D.R. Laybutt, *Mechanisms of beta-cell dedifferentiation in diabetes: recent findings and future research directions*. *J Endocrinol*, 2018. **236**(2): p. R109-R143.
172. Brereton, M.F., et al., *Reversible changes in pancreatic islet structure and function produced by elevated blood glucose*. *Nat Commun*, 2014. **5**: p. 4639.
173. Chakravarthy, H., et al., *Converting Adult Pancreatic Islet alpha Cells into beta Cells by Targeting Both Dnmt1 and Arx*. *Cell Metab*, 2017. **25**(3): p. 622-634.
174. Conrad, E., R. Stein, and C.S. Hunter, *Revealing transcription factors during human pancreatic beta cell development*. *Trends Endocrinol Metab*, 2014. **25**(8): p. 407-14.
175. Hang, Y. and R. Stein, *MafA and MafB activity in pancreatic beta cells*. *Trends Endocrinol Metab*, 2011. **22**(9): p. 364-73.
176. Artner, I., et al., *MafA and MafB regulate genes critical to beta-cells in a unique temporal manner*. *Diabetes*, 2010. **59**(10): p. 2530-9.

177. Artner, I., et al., *MafB is required for islet beta cell maturation*. Proc Natl Acad Sci U S A, 2007. **104**(10): p. 3853-8.
178. Zhang, C., et al., *MafA is a key regulator of glucose-stimulated insulin secretion*. Mol Cell Biol, 2005. **25**(12): p. 4969-76.
179. Guo, S., et al., *Inactivation of specific beta cell transcription factors in type 2 diabetes*. J Clin Invest, 2013. **123**(8): p. 3305-16.
180. Matsuoka, T.A., et al., *The MafA transcription factor appears to be responsible for tissue-specific expression of insulin*. Proc Natl Acad Sci U S A, 2004. **101**(9): p. 2930-3.
181. Wang, H., et al., *MAFA controls genes implicated in insulin biosynthesis and secretion*. Diabetologia, 2007. **50**(2): p. 348-58.
182. Artner, I., et al., *MafB: an activator of the glucagon gene expressed in developing islet alpha- and beta-cells*. Diabetes, 2006. **55**(2): p. 297-304.
183. Vanhoose, A.M., et al., *MafA and MafB regulate Pdx1 transcription through the Area II control region in pancreatic beta cells*. J Biol Chem, 2008. **283**(33): p. 22612-9.
184. Nishimura, W., et al., *A switch from MafB to MafA expression accompanies differentiation to pancreatic beta-cells*. Dev Biol, 2006. **293**(2): p. 526-39.
185. Miki, R., et al., *Fate maps of ventral and dorsal pancreatic progenitor cells in early somite stage mouse embryos*. Mech Dev, 2012. **128**(11-12): p. 597-609.
186. Jennings, R.E., et al., *Development of the human pancreas from foregut to endocrine commitment*. Diabetes, 2013. **62**(10): p. 3514-22.
187. Holland, A.M., et al., *Experimental control of pancreatic development and maintenance*. Proc Natl Acad Sci U S A, 2002. **99**(19): p. 12236-41.
188. Gao, T., et al., *Pdx1 maintains beta cell identity and function by repressing an alpha cell program*. Cell Metab, 2014. **19**(2): p. 259-71.
189. Gradwohl, G., et al., *neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas*. Proc Natl Acad Sci U S A, 2000. **97**(4): p. 1607-11.
190. Huang, H.P., et al., *Regulation of the pancreatic islet-specific gene BETA2 (neuroD) by neurogenin 3*. Mol Cell Biol, 2000. **20**(9): p. 3292-307.
191. Smith, S.B., et al., *Neurogenin3 and hepatic nuclear factor 1 cooperate in activating pancreatic expression of Pax4*. J Biol Chem, 2003. **278**(40): p. 38254-9.
192. Collombat, P., et al., *The simultaneous loss of Arx and Pax4 genes promotes a somatostatin-producing cell fate specification at the expense of the alpha- and beta-cell lineages in the mouse endocrine pancreas*. Development, 2005. **132**(13): p. 2969-80.
193. Mfopou, J.K., et al., *Recent advances and prospects in the differentiation of pancreatic cells from human embryonic stem cells*. Diabetes, 2010. **59**(9): p. 2094-101.
194. Adams, J.D. and A. Vella, *What Can Diabetes-Associated Genetic Variation in TCF7L2 Teach Us About the Pathogenesis of Type 2 Diabetes?* Metab Syndr Relat Disord, 2018. **16**(8): p. 383-389.

195. Chen, X., et al., *The Diabetes Gene and Wnt Pathway Effector TCF7L2 Regulates Adipocyte Development and Function*. *Diabetes*, 2018. **67**(4): p. 554-568.
196. Jin, T., *Current Understanding on Role of the Wnt Signaling Pathway Effector TCF7L2 in Glucose Homeostasis*. *Endocr Rev*, 2016. **37**(3): p. 254-77.
197. Grant, S.F., et al., *Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes*. *Nat Genet*, 2006. **38**(3): p. 320-3.
198. Liu, Z. and J.F. Habener, *Wnt signaling in pancreatic islets*. *Adv Exp Med Biol*, 2010. **654**: p. 391-419.
199. Jin, T. and L. Liu, *The Wnt signaling pathway effector TCF7L2 and type 2 diabetes mellitus*. *Mol Endocrinol*, 2008. **22**(11): p. 2383-92.
200. Shu, L., et al., *Transcription factor 7-like 2 regulates beta-cell survival and function in human pancreatic islets*. *Diabetes*, 2008. **57**(3): p. 645-53.
201. da Silva Xavier, G., et al., *TCF7L2 regulates late events in insulin secretion from pancreatic islet beta-cells*. *Diabetes*, 2009. **58**(4): p. 894-905.
202. Doria, A., M.E. Patti, and C.R. Kahn, *The emerging genetic architecture of type 2 diabetes*. *Cell Metab*, 2008. **8**(3): p. 186-200.
203. Ray, M.K., et al., *Beta cell-specific ablation of target gene using Cre-loxP system in transgenic mice*. *J Surg Res*, 1999. **84**(2): p. 199-203.
204. Magnuson, M.A. and A.B. Osipovich, *Pancreas-specific Cre driver lines and considerations for their prudent use*. *Cell Metab*, 2013. **18**(1): p. 9-20.
205. Feil, R., et al., *Ligand-activated site-specific recombination in mice*. *Proc Natl Acad Sci U S A*, 1996. **93**(20): p. 10887-90.
206. Herrera, P.L., *Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages*. *Development*, 2000. **127**(11): p. 2317-22.
207. Wicksteed, B., et al., *Conditional gene targeting in mouse pancreatic  $\beta$ -Cells: analysis of ectopic Cre transgene expression in the brain*. *Diabetes*, 2010. **59**(12): p. 3090-8.
208. Song, J., et al., *Brain expression of Cre recombinase driven by pancreas-specific promoters*. *Genesis*, 2010. **48**(11): p. 628-34.
209. Basabe, J., et al., *Studies of insulin secretion in the perfused rat pancreas. Effect of diazoxide and A025*. *Diabetes*, 1970. **19**(4): p. 271-81.
210. Wargent, E.T., *Measurement of Insulin Secretion Using Pancreas Perfusion in the Rodent, in Type 2 Diabetes: Methods and Protocols*, C.J. Stocker, Editor. 2020, Springer New York: New York, NY. p. 281-297.
211. Egido, E.M., et al., *Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas*. *Regul Pept*, 2009. **152**(1-3): p. 61-6.
212. Goncz, E., et al., *Orexin-A inhibits glucagon secretion and gene expression through a Foxo1-dependent pathway*. *Endocrinology*, 2008. **149**(4): p. 1618-26.
213. de Heer, J., et al., *Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin*



- (receptor subtype 2) in the perfused rat pancreas. *Diabetologia*, 2008. **51**(12): p. 2263-70.
214. Emilsson, V., et al., *Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion*. *Diabetes*, 1997. **46**(2): p. 313-6.
215. Tseng, C.C., X.Y. Zhang, and M.M. Wolfe, *Effect of GIP and GLP-1 antagonists on insulin release in the rat*. *Am J Physiol*, 1999. **276**(6): p. E1049-54.
216. Sakmann, B. and E. Neher, *Patch clamp techniques for studying ionic channels in excitable membranes*. *Annu Rev Physiol*, 1984. **46**: p. 455-72.
217. Neher, E. and B. Sakmann, *Single-channel currents recorded from membrane of denervated frog muscle fibres*. *Nature*, 1976. **260**(5554): p. 799-802.
218. Rubaiy, H.N., *A Short Guide to Electrophysiology and Ion Channels*. *J Pharm Pharm Sci*, 2017. **20**: p. 48-67.
219. Ashcroft, F.M. and P. Rorsman, *Electrophysiology of the pancreatic beta-cell*. *Prog Biophys Mol Biol*, 1989. **54**(2): p. 87-143.
220. Gentet, L.J., G.J. Stuart, and J.D. Clements, *Direct measurement of specific membrane capacitance in neurons*. *Biophys J*, 2000. **79**(1): p. 314-20.
221. Neher, E. and A. Marty, *Discrete changes of cell membrane capacitance observed under conditions of enhanced secretion in bovine adrenal chromaffin cells*. *Proc Natl Acad Sci U S A*, 1982. **79**(21): p. 6712-6.
222. Eliasson, L., et al., *Endocytosis of secretory granules in mouse pancreatic beta-cells evoked by transient elevation of cytosolic calcium*. *J Physiol*, 1996. **493** ( Pt 3): p. 755-67.
223. Braun, M., et al., *Regulated exocytosis of GABA-containing synaptic-like microvesicles in pancreatic beta-cells*. *J Gen Physiol*, 2004. **123**(3): p. 191-204.
224. Gopel, S.O., et al., *Regulation of glucagon release in mouse -cells by KATP channels and inactivation of TTX-sensitive Na<sup>+</sup> channels*. *J Physiol*, 2000. **528**(Pt 3): p. 509-20.
225. Braun, M., et al., *Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion*. *Diabetes*, 2008. **57**(6): p. 1618-28.
226. Velasco-Estevez, M., et al., *Piezol regulates calcium oscillations and cytokine release from astrocytes*. *Glia*, 2020. **68**(1): p. 145-160.
227. Han, Y., et al., *Mechanosensitive ion channel Piezo1 promotes prostate cancer development through the activation of the Akt/mTOR pathway and acceleration of cell cycle*. *Int J Oncol*, 2019. **55**(3): p. 629-644.
228. Romac, J.M., et al., *Piezol is a mechanically activated ion channel and mediates pressure induced pancreatitis*. *Nat Commun*, 2018. **9**(1): p. 1715.
229. Blythe, N.M., et al., *Mechanically activated Piezo1 channels of cardiac fibroblasts stimulate p38 mitogen-activated protein kinase activity and interleukin-6 secretion*. *J Biol Chem*, 2019. **294**(46): p. 17395-17408.

230. Gudipaty, S.A., et al., *Mechanical stretch triggers rapid epithelial cell division through Piezo1*. Nature, 2017. **543**(7643): p. 118-121.
231. Bae, C., et al., *Human PIEZO1 Ion Channel Functions as a Split Protein*. PLoS One, 2016. **11**(3): p. e0151289.
232. Jansson, L., et al., *Pancreatic islet blood flow and its measurement*. Ups J Med Sci, 2016. **121**(2): p. 81-95.
233. Semino, M.C., et al., *Early changes in the rat pancreatic B cell size induced by glucose*. Acta Anat (Basel), 1990. **138**(4): p. 293-6.
234. Best, L., *Glucose-induced electrical activity in rat pancreatic beta-cells: dependence on intracellular chloride concentration*. J Physiol, 2005. **568**(Pt 1): p. 137-44.
235. Syeda, R., et al., *Chemical activation of the mechanotransduction channel Piezo1*. Elife, 2015. **4**.
236. Li, J., B. Hou, and D.J. Beech, *Endothelial Piezo1: life depends on it*. Channels (Austin), 2015. **9**(1): p. 1-2.
237. Ashcroft, F.M., D.E. Harrison, and S.J. Ashcroft, *Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells*. Nature, 1984. **312**(5993): p. 446-8.
238. Miki, T., et al., *Defective insulin secretion and enhanced insulin action in KATP channel-deficient mice*. Proc Natl Acad Sci U S A, 1998. **95**(18): p. 10402-6.
239. Bacova, Z., et al., *Different signaling pathways involved in glucose- and cell swelling-induced insulin secretion by rat pancreatic islets in vitro*. Cell Physiol Biochem, 2005. **16**(1-3): p. 59-68.
240. Wierup, N., et al., *Cocaine- and amphetamine-regulated transcript (CART) is expressed in several islet cell types during rat development*. J Histochem Cytochem, 2004. **52**(2): p. 169-77.
241. Shcherbina, L., et al., *Endogenous beta-cell CART regulates insulin secretion and transcription of beta-cell genes*. Mol Cell Endocrinol, 2017. **447**: p. 52-60.
242. Sathanoori, R., et al., *Cocaine- and amphetamine-regulated transcript (CART) protects beta cells against glucotoxicity and increases cell proliferation*. J Biol Chem, 2013. **288**(5): p. 3208-18.
243. Lacroix, J.J., W.M. Botello-Smith, and Y. Luo, *Probing the gating mechanism of the mechanosensitive channel Piezo1 with the small molecule Yoda1*. Nat Commun, 2018. **9**(1): p. 2029.
244. Yoneda, M., et al., *PIEZO1 and TRPV4, which Are Distinct Mechanosensors in the Osteoblastic MC3T3-E1 Cells, Modify Cell-Proliferation*. Int J Mol Sci, 2019. **20**(19).
245. Gong, H.C., et al., *Tissue-specific expression and gabapentin-binding properties of calcium channel alpha2delta subunit subtypes*. J Membr Biol, 2001. **184**(1): p. 35-43.
246. Mastrolia, V., et al., *Loss of alpha2delta-1 Calcium Channel Subunit Function Increases the Susceptibility for Diabetes*. Diabetes, 2017.

247. Khosravani, H. and G.W. Zamponi, *Voltage-gated calcium channels and idiopathic generalized epilepsies*. *Physiol Rev*, 2006. **86**(3): p. 941-66.
248. Segev, N., *Trafficking inside cells*. Springer Science-Business Media, 2009.
249. Buda, P., et al., *Eukaryotic translation initiation factor 3 subunit e controls intracellular calcium homeostasis by regulation of cav1.2 surface expression*. *PLoS One*, 2013. **8**(5): p. e64462.
250. Conrad, R., et al., *Rapid Turnover of the Cardiac L-Type CaV1.2 Channel by Endocytic Recycling Regulates Its Cell Surface Availability*. *iScience*, 2018. **7**: p. 1-15.
251. Hendrich, J., et al., *Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin*. *Proc Natl Acad Sci U S A*, 2008. **105**(9): p. 3628-33.
252. Soldatov, N.M., *Molecular Determinants of Cav1.2 Calcium Channel Inactivation*. *ISRN Mol Biol*, 2012. **2012**: p. 691341.
253. Pan, J.Y., et al., *Regulation of L-type Ca<sup>2+</sup> Channel Activity and Insulin Secretion by Huntingtin-associated Protein 1*. *J Biol Chem*, 2016. **291**(51): p. 26352-26363.
254. Raifman, T.K., et al., *Protein kinase C enhances plasma membrane expression of cardiac L-type calcium channel, CaV1.2*. *Channels (Austin)*, 2017. **11**(6): p. 604-615.
255. Scholl, J.H., R. van Eekeren, and E.P. van Puijenbroek, *Six cases of (severe) hypoglycaemia associated with gabapentin use in both diabetic and non-diabetic patients*. *Br J Clin Pharmacol*, 2015. **79**(5): p. 870-1.
256. Kazim, A.S., et al., *Palmitoylation of Ca(2+) channel subunit CaVbeta2a induces pancreatic beta-cell toxicity via Ca(2+) overload*. *Biochem Biophys Res Commun*, 2017. **491**(3): p. 740-746.
257. Ye, Y., et al., *The TCF7L2-dependent high-voltage activated calcium channel subunit alpha2delta-1 controls calcium signaling in rodent pancreatic beta-cells*. *Mol Cell Endocrinol*, 2020. **502**: p. 110673.
258. Calcrafft, P.J., et al., *NAADP mobilizes calcium from acidic organelles through two-pore channels*. *Nature*, 2009. **459**(7246): p. 596-600.
259. Namkung, Y., et al., *Requirement for the L-type Ca(2+) channel alpha(1D) subunit in postnatal pancreatic beta cell generation*. *J Clin Invest*, 2001. **108**(7): p. 1015-22.
260. Ghosh, D., et al., *Dynamic L-type CaV1.2 channel trafficking facilitates CaV1.2 clustering and cooperative gating*. *Biochim Biophys Acta Mol Cell Res*, 2018. **1865**(9): p. 1341-1355.
261. Srinivasan, A., et al., *In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system*. *Cell Death Differ*, 1998. **5**(12): p. 1004-16.
262. Lavrik, I.N., A. Golks, and P.H. Krammer, *Caspases: pharmacological manipulation of cell death*. *J Clin Invest*, 2005. **115**(10): p. 2665-72.
263. Chen, A., et al., *The Role of p21 in Apoptosis, Proliferation, Cell Cycle Arrest, and Antioxidant Activity in UVB-Irradiated Human HaCaT Keratinocytes*. *Med Sci Monit Basic Res*, 2015. **21**: p. 86-95.

264. Cinti, F., et al., *Evidence of beta-Cell Dedifferentiation in Human Type 2 Diabetes*. J Clin Endocrinol Metab, 2016. **101**(3): p. 1044-54.
265. Fukaya, M., et al., *Spatial diversity in gene expression for VDCCgamma subunit family in developing and adult mouse brains*. Neurosci Res, 2005. **53**(4): p. 376-83.
266. Naranjo, J.R. and B. Mellstrom, *Ca<sup>2+</sup>-dependent transcriptional control of Ca<sup>2+</sup> homeostasis*. J Biol Chem, 2012. **287**(38): p. 31674-80.
267. Shalizi, A., et al., *A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation*. Science, 2006. **311**(5763): p. 1012-7.
268. Jing, X., et al., *CaV2.3 calcium channels control second-phase insulin release*. J Clin Invest, 2005. **115**(1): p. 146-54.
269. Wang, Z., et al., *Pancreatic beta cell dedifferentiation in diabetes and redifferentiation following insulin therapy*. Cell Metab, 2014. **19**(5): p. 872-82.
270. Talchai, C., et al., *Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure*. Cell, 2012. **150**(6): p. 1223-34.
271. Susztak, K., et al., *Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease*. Diabetes, 2004. **53**(3): p. 784-94.
272. Wu, J., R. Goyal, and J. Grandl, *Localized force application reveals mechanically sensitive domains of Piezo1*. Nat Commun, 2016. **7**: p. 12939.
273. Zhang, E., et al., *Dynamic magnetic fields remote-control apoptosis via nanoparticle rotation*. ACS Nano, 2014. **8**(4): p. 3192-201.
274. Qiu, Z., et al., *The Mechanosensitive Ion Channel Piezo1 Significantly Mediates In Vitro Ultrasonic Stimulation of Neurons*. iScience, 2019. **21**: p. 448-457.
275. Milstein, A.D., et al., *TARP subtypes differentially and dose-dependently control synaptic AMPA receptor gating*. Neuron, 2007. **55**(6): p. 905-18.





## About the Author

---



Yingying Ye is a biomedical graduate from Lund University. Her main research interest is to investigate islet pathophysiology in type 2 diabetes. The focus on her thesis work was to explore the novel insulin secretion pathway involving mechanosensitive channel Piezo1 in pancreatic  $\beta$ -cells and the roles of  $\text{Ca}^{2+}$  channel subunits in regulating  $\beta$ -cell function.